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Natural products, or secondary metabolites, usually refer to bioactive small molecules produced 
by microorganisms or plants. To date, thousands of natural products have been characterized which 
reveal diverse structures and bioactivities, making it an ideal resource for discovering drug leads 
and mining biocatalysts. The advances in bioinformatics and DNA sequencing technology in the 
21st century enables the prediction of tremendously large numbers of biosynthetic pathways for 
natural products directly from genomic database, which indicates Nature’s great potential of 
making these molecules remains to be explored. However, most of these uncharacterized pathways 
are naturally under negative regulation or encoded by uncultivable microorganisms and thus turn 
into “dark matters” for natural product discovery.  
 
Pathway refactoring serves as an invaluable synthetic biology tool for natural product discovery, 
characterization, and engineering. However, the complicated and laborious molecular biology 
techniques largely hinder its application in natural product research, especially in a high-
throughput manner. Therefore, I developed a plug-and-play pathway refactoring workflow for 
high-throughput, flexible pathway construction, and expression in both Escherichia coli and 
Saccharomyces cerevisiae. The modular design not only enables the system to accommodate 
pathways with different number of genes, but also facilitates gene deletion and replacement. As 
proof of concept, a total of 96 pathways for combinatorial carotenoid biosynthesis were built 
successfully.  
 
The plug-and-play workflow was then used for discovering lanthipeptides and glycocins, both are 
groups of ribosomally synthesized post-translationally modified peptides (RiPPs) with various 
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antimicrobial activities. A Class IV lanthipeptide with an unusual ring topology was successfully 
discovered, and its cyclization mechanism was elucidated in vitro. In addition, four novel 
glycocins were also discovered and one of them was unprecedentedly di-glucosylated on a single 
serine. Further bioactivity characterization of glycocins revealed that three of them exhibit narrow 
antimicrobial spectrum and implied the existence of new biological targets of glycocins. 
 
In addition, I also characterized the biosynthesis of heat stable antifungal factor (HSAF), a 
polyketide which belongs to the polycyclic tetramate macrolactam (PTM) series. Previously Zhao 
group discovered a PTM from Streptomyces griseus and characterized its biosynthesis, indicating 
a parallel biosynthetic mechanism. To further explore if this is general for the biosynthesis of all 
PTMs, I made four constructs which are supposed to make different intermediates in the HSAF 
biosynthesis.  After successful isolation and structural characterization of these intermediates, the 
biosynthetic mechanism of HSAF was elucidated, which clearly supports the assumption that the 
HSAF pathway also has a parallel biosynthetic mechanism.  
 
Finally, to accelerate the engineering of streptomycetes to be ideal chassis for natural product 
discovery and overproduction, I applied the clustered regularly interspaced short palindromic 
repeats (CRIPSR)-dCas9 system for gene repression in both Streptomyces lividans 66 and 
Streptomyces albus J1074. By fusing the RNA polymerase omega factor (RNAP-ω) to dCas9, it 
was able to activate the silent undecylprodigiosin (RED) gene cluster in S. lividans 66. In addition, 
to further engineer the CRISPR-dCas9 system to exert titratable repression, an inducible promoter 
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Chapter 1: Overview for Natural Product Discovery Through Synthetic 
Biology Approaches 
1.1 Natural Product Discovery Through Genome Mining 
Since the discovery of penicillin by Fleming in 1928, natural products have been playing an 
indispensable role in the treatment of human, animal and plant diseases for almost a century (1, 2). 
Natural products, particularly secondary metabolites from microorganisms, offer their producers 
advantages for growth and propagation in complex environments. For example, antibiotics, which 
can kill or stop the growth of a broad or narrow spectrum of target organisms, enable their 
producers to be more competitive for nutrients. This unique feature of antibiotics was soon 
explored in clinic to control pathogens. Today, with thousands of natural products being 
discovered with various bioactivities, natural products and their semisynthetic derivatives are 
widely used for the treatment of multiple kinds of diseases ranging from cancer to high cholesterol. 
Besides the treatment of human diseases, natural products are also used in the agriculture sector as 
herbicides, insecticides, and fungicides (3). 
 
Traditionally, natural products were discovered through a combination of separation techniques 
and bioactivity screening. Using this strategy, the discovery of natural products entered its Golden 
Age in the period from 1950s to 1960s. However, since then, the rate for natural products discovery 
has been significantly decreased due to the inherent drawbacks of the traditional method. One of 
its biggest drawbacks is the high rediscovery rate (4). Importantly, it was found that there are 
numerous silent natural product biosynthetic gene clusters (BGCs) in a wide variety of 
microorganisms. The biosynthesis of natural products is usually under complex yet unknown 
regulations and therefore cannot happen under inappropriate culturing conditions. With the recent 
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advances of next generation sequencing and bioinformatic tools for BGC prediction, it has become 
clear that the potential of Nature to produce natural products was largely underestimated in the 
past. Take Streptomyces species as an example, around 20-50 putative BGCs can be predicted 
from each genome, while only a few of them have been characterized (5, 6). Moreover, as natural 
products potentially produced by unculturable microorganisms, such as some symbionts of marine 
animals and plants, are largely hindered from being discovered due to the limited availability of 
materials, the number of natural products that can be produced by uncharacterized BGCs are far 
more than the number of known natural products. 
 
To activate silent BGCs as well as to make the natural product discovery process more efficient, 
many synthetic biology tools have been developed in the past decade. In this chapter, I will 
introdcue the synthetic biology strategies and tools developed for activating silent BGCs for 
discovery of natural products (Figure 1.1). In addition, I will also provide some background about 
the classification of natural products and mainly focus on introducing ribosomally synthesized and 
post-translationally modified peptides (RiPPs) and polyketides. Tools and strategies for optimizing 
the productivity of natural products will also be mentioned briefly. 
 
1.2 Synthetic Biology Approaches for Natural Product Discovery 
1.2.1 Advantages for Natural Product Discovery Through Heterologous Expression of 
BGCs 
There are generally two strategies to address the limitations of traditional genome mining methods 
mentioned above. One is to turn on the silent BGCs through genetic manipulation of the native 
producer to rewire the corresponding negative regulation. While the other one is to heterologously 
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express the BGC in a model organism through direct cloning or refactoring (7). Although many 
natural products were successfully discovered through manipulation of native producers, there are 
several shortcomings associated with this strategy. For example, for BGCs in microorganisms 
lacking proper culturing methods in the laboratory, the isolation of target compounds through cell 
cultivation can hardly be achieved. Developing a cultivation method for a specific microorganism 
is also challenging because the nutrients critical for its survival are not predictable and mimicking 
the environment from where the microorganism was isolated seems to be a daunting task. 
Moreover, although many transformation or conjugation methods and broad host range genetic 
elements are available, the lack of genetic tools for most microorganisms remains the biggest 
challenge for activating silent BGCs in native producers.  
 
However, such issues can be readily solved by expressing the BGC of interest in a heterologous 
host which provides a similar in vivo environment for successful gene expression and product 
synthesis as the native producer yet has well-established genetic manipulation tools for cloning, 
refactoring, and introduction of foreign BGCs. These good features not only make heterologous 
expression associated methods as alternative ways to native producer associated methods, but also 
shed light on developing general workflow for genome mining as all experiments involved have 
the potential to be standardized and therefore automatable. In light of the rapidly developing 
automation technologies for synthetic biology as well as the automation-based high-throughput 
drug lead screening technologies that are well-established to date, automation of the genome 




1.2.2 Direct Cloning 
Direct cloning was a widely used approach for BGC heterologous expression. Through simply 
cloning the whole BGC into an appropriate vector for its replication in the heterologous host, direct 
cloning appears to be one of the most widely used methods for heterologous expression. Although 
in most cases little changes are introduced to regulatory elements in the BGC, negative regulations 
can be bypassed, albeit not guaranteed by simply changing the in vivo environment for expression. 
While traditionally it is achieved by creating fosmid or cosmid libraries and screening for clones 
with target BGCs, which can be tedious and time consuming, direct cloning aims to specifically 
clone the target BGC by developing cutting-edge synthetic biology tools. Through integration of 
the recombineering sites to the target BGC, site specific recombineering systems such as Cre/loxP 
and phage φBT1 integrase system can separate the target BGC from the genome and circularize it 
as a plasmid (9, 10). By using the clustered regularly interspaced short palindromic repeats 
(CRISPR)-Cas9 system, the target gene cluster can also be specifically cleaved from the genome. 
Jiang and co-workers developed a Cas9-assisted targeting of chromosome segments (CATCH) 
method for direct cloning of BGCs (11, 12). The target BGC is cleaved from intact genomic DNA 
by Cas9 in vitro and then ligated with a cloning vector through Gibson assembly. In addition to 
site specific integration or cleavage, the target BGC can also be selected from sheared genomic 
DNA fragments through transforming helper microorganisms with strong recombineering system, 
such as E. coli with the phage Rec/ET system or Saccharomyces cerevisiae (13, 14) (Figure 1.2). 
 
Although direct cloning has been proven to be successful for bypassing the native regulatory 
system in many cases (15), its main limitation is still apparent for the heterologous expression of 
BGCs. As all putative regulatory elements in the BGCs are untouched in most cases, and the 
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regulatory mechanism for the expression of biosynthetic genes remain as a black box in most cases, 
the direct cloning strategies for successful expression of BGCs are more or less a trial and error 
process. The heterologous hosts are usually phylogenetically close to the native producers which 
provide similar environments for biosynthetic genes expression and enzymatic reactions, while the 
negative regulations which exist in the native producers are often missing in heterologous hosts. 
Even with continuous efforts for developing model hosts, the choices for expressing unique BGCs 
are still very limited, therefore lowering the successful rate for natural product discovery through 
direct cloning. 
 
1.2.3 Pathway Refactoring 
Pathway refactoring was used as an alternative strategy to direct cloning for natural product 
discovery through heterologous expression (3). By replacing the unknown regulatory elements 
with well characterized ones in the model hosts, the repression can be bypassed. Although pathway 
refactoring can be accomplished through stepwise ligation into the existing expression construct 
and co-transformation, it is a relatively low efficiency strategy and the number of genes which can 
be refactored is limited (16-18). Therefore, such a strategy typically requires a powerful DNA 
assembly method that can be used for reconstruction of the target BGC through assembly of 
multiple DNA fragments, including biosynthetic genes and regulatory elements, in a user-defined 
order (Figure 1.3). Considering that several tools developed for both in vitro (e.g. Gibson 
Assembly (19) and Golden Gate assembly (20)) and in vivo (e.g. DNA assembler (21)) DNA 
assembly can assemble multiple DNA fragments with high efficiency, there is great potential that 
such methods can be customized as standardized workflows for pathway refactoring and applied 




One strategy to refactor a target BGC is through in vivo recombination, as demonstrated both in E. 
coli and S. cerevisiae.  Apel and coworkers developed an artificial gene operon assembly system 
(AGOS) by using the Red/ET encoded E. coli (23). Biosynthetic genes or operons can be cloned 
into the entry plasmids harboring built-in promoters and terminators by restriction digestion-
ligation. As all entry plasmids have different pairs of homology arms to the destination plasmid, 
different operons are integrated into the destination plasmid through recombination stepwisely in 
the Red/ET E. coli strain.  
 
While the homologous recombination mechanism in E. coli has been used for pathway refactoring, 
the homologous recombination mechanism in S. cerevisiae has also been used for pathway 
refactoring in different ways. Brady and coworkers developed a method in which bidirectional S. 
cerevisiae promoters with different auxotrophic selection markers were built. In order to replace 
the native promoters in the BGC, homology arms to the target sites on the BGC are added to both 
ends of the bidirectional promoters and co-transformed with the gene cluster to S. cerevisiae. The 
successful replacement of native promoters can be isolated by auxotrophic selection. Such a 
method can insert up to three bidirectional promoters in one batch, if long homology arms (>500 
bp) are used (24). Later on, they improved this method by integrating CRIPSR/Cas9 into this 
workflow and developed a yeast-based promoter engineering platform (mCRISTAR) (25). Due to 
the double strand breaks induced by CRIPSR/Cas9 during promoter integration, it has a significant 
increase in the recombination efficiency. Also by taking advantage of the highly efficient 
homologous recombination process in S. cerevisiae, Zhao and coworkers developed a method 
called DNA assembler where all DNA fragments, including regulatory parts and biosynthetic 
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genes, are prepared with homology arms to each other (21). After co-transformation into S. 
cerevisiae, all DNA fragments can be assembled into one construct. Through involving different 
parts for replication and selection, the final construct can be transferred into a different host for 
expression (26). By using this method, Zhao and coworkers successfully activated a silent 
polycyclic tetramate macrolactam (PTM) BGC from S. griseus in S. lividans and characterized the 
associated compounds (27).  
 
Recently, a similar strategy has been applied for heterologous expression of fungus BGCs in S. 
cerevisiae through development of a heterologous expression (HEx) platform (28). Through 
pairing promoters and terminators as standard parts which serve as linkers for biosynthetic genes, 
fungal gene clusters can be simply refactored for expression in S. cerevisiae through transforming 
the biosynthetic genes and the corresponding standard parts as linear DNA into S. cerevisiae 
directly. To develop a suitable platform S. cerevisiae strain, they discovered and characterized 
pADH2-like promoters with various strength, which are auto-inducible when glucose and other 
fermentable carbon sources are converted to nonfermentable carbon sources. The delayed 
induction phenotype was confirmed by using these promoters for green fluorescence protein (GFP) 
expression. In addition, they developed an improved S. cerevisiae strain (DHY) by repairing the 
mitochondrial genome instability and deficiency of sporulation, deleting protease genes and 
integrating several genes for essential posttranslational modification enzymes (holo-ACP synthase 
and cytochrome P450 reductase). As a result, 22 new compounds were successfully detected from 




In addition to in vivo DNA assembly methods, in vitro DNA assembly methods such as Gibson 
Assembly and Golden Gate assembly have also been used for pathway refactoring when used 
individually or in combination. By using Golden Gate assembly and Gibson Assembly together, 
Zhao and coworkers successfully refactored a 13-gene phosphonate BGC for heterologous 
expression in S. lividans and isolated a novel phosphonoacetic acid (29). In addition, Voigt and 
coworkers used Golden Gate assembly for refactoring silent BGCs such as the pyrrolnitrin BGC 
for expression in E. coli (30). Besides the activation of silent BGCs, through pathway refactoring 
with rational design, the performance of the pathway in heterologous hosts can be significantly 
improved. The nitrogen fixation gene cluster (nif) identified from Klebsiella oxytoca has 
undetectable activity when transformed into E. coli directly. However, after refactoring, 57% of 
the wild-type activity can be recovered in E. coli (30). 
 
1.3 Ribosomally Synthesized and Post-translationally Modified Peptides (RiPPs) 
Based on the structural and biosynthetic features of natural products discovered in the past century, 
natural products were traditionally divided into four categories: polyketides (PKs), nonribosomal 
peptides (NRPs), terpenoids and alkaloids. However, since the start of the 21st century, particularly 
due to the extensive application of advanced DNA sequencing technologies, another major 
category of natural products called ribosomally synthesized and post-translationally modified 
peptides (RiPPs) was identified. Unlike the NRP which requires the nonribosomal peptide synthase 
(NRPS) to build the skeleton of the final product, the biosynthesis of RiPPs starts from the 
expression of precursor peptides which commonly consist of two parts: leader peptide and core 
peptide. While post-translational modifications (PTMs) take place at the core peptide, the leader 
peptide serves as the recognition site for PTM enzymes. After all PTMs are finished, the leader 
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peptide should be cleaved off and the core peptide is transferred outside the cell to exert its function. 
To date, RiPPs with diverse PTMs have been discovered from all three domains of life and these 
RiPPs were also subdivided into more than 20 families (31). RiPPs also reveal diverse bioactivities 
such as  antimicrobial, antifungal, and antiviral activities, making them an ideal resource for drug 
leads and some RiPPs are currently under clinical trials (32).   
1.4 Polyketides 
Polyketides are a major family of natural products with a broad range of bioactivities that have 
been studied for decades. The biosynthesis of polyketides starts from the formation of the 
polyketide skeleton which is catalyzed by polyketide syntheases (PKSs) following with various 
tailoring reactions such as oxidation and cyclization. PKSs assemble small acetic acid-type acyl 
building blocks, such as malonyl-CoA, into polyketides through C–C bonds. A common PKS 
consists of three types of core domains: acyltransferase (AT) domain, a ketosynthase (KS) domain 
and a carrier protein (CP) domain. The AT domain recognizes a specific acyl starter or extender 
unit and catalyzes its transfer onto the phosphopantetheine arm of the CP to form a thioester 
conjugate. The KS domain catalyzes a Claisen type condensation between an extender unit and a 
growing acyl chain. Sometimes the extending chain is also processed by ketoreductase (KR), 
dehydratase (DH) and enoylreductase (ER) domains, which results in the formation of an α,β-
double bond or a fully reduced methylene group. Polyketides have reveal diverse bioactivities 
including antimicrobial, antifungal and anticancer functions (33). For example, tetracycline is a 
widely used broad spectrum polyketide antibiotic produced by Streptomyces and daptomycin is 
another polyketide antibiotic which is usually used for life-threatening infections (34, 35). 
Epothilone is a 16-membered polyketide macrolactone and one of its analog ixabepilone has been 
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approved for cancer treatment (36). Therefore, it would be of great interest to discover novel 
polyketide natural products and study the biosynthetic mechanism. 
 
1.5 Project Overview 
My thesis research mainly focuses on developing and applying synthetic biology tools to accelerate 
natural product discovery. Throughout my work, I have developed a plug-and-play pathway 
refactoring workflow for natural product research. This workflow was then used for the discovery 
of glycocins and Class IV lanthipeptides, which reveal interesting structural features and 
bioactivities. In addition, in vivo and in vitro investigation of biosynthetic mechanisms were 
carried out for heat stable antifungal factor (HSAF) and a novel Class IV lanthipeptide respectively. 
Finally, I have obtained some preliminary data on the development of CRISPR-based approaches 
for gene regulation in Streptomycetes.  
 
Chapter 2 describes the development of a plug-and-play pathway refactoring workflow for high-
throughput, flexible pathway construction, and expression in both E. coli and S. cerevisiae. 
Biosynthetic genes were firstly cloned into pre-assembled helper plasmids with promoters and 
terminators, resulting in a series of expression cassettes. These expression cassettes were further 
assembled using Golden Gate reaction to generate fully refactored pathways. The inclusion of 
spacer plasmids in this system would not only increase the flexibility for refactoring pathways 
with different number of genes, but also facilitate gene deletion and replacement. As a proof of 
concept, the zeaxanthin biosynthetic pathway was refactored with more than 95% fidelity and 
successfully expressed in S. cerevisiae. Moreover, in order to further prove the flexibility of this 
workflow for generating gene knockouts, another three zeaxanthin pathways with different gene 
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knockouts were also constructed and the corresponding intermediates were isolated after 
expression in S. cerevisiae. This workflow was also proven to be useful for combinatorial 
biosynthesis by refactoring another three carotenoid pathways with different gene combinations 
for expression in E. coli.  To demonstrate its application for high-throughput pathway refactoring, 
a total of 96 pathways for combinatorial carotenoid biosynthesis were built successfully. 
 
Chapter 3 describes the application of the pathway refactoring workflow in Chapter 2 for 
discovering glycocins (glycosylated bacteriocins). Glycocins are a family of RiPPs with 
antimicrobial activities against pathogens of interest, including methicillin–resistant 
Staphylococcus aureus, representing a promising source of new antibiotics. Glycocins are still 
largely underexplored, and thus far, only six glycocins are known. In this chapter, 50 putative 
glycocin biosynthetic gene clusters were identified by genome mining and six of them with distinct 
features were chosen for further investigation. Through two rounds of plug-and-play pathway 
refactoring and expression in E. coli BL21(DE3), four systems produced novel glycocins. Further 
structural characterization revealed that one of them, which belongs to the enterocin 96-type 
glycocins, was diglucosylated on a single serine. The other three compounds belong to the 
SunA/ThuA-type glycocins and exhibit an antimicrobial spectrum narrower than that of sublancin, 
the best characterized member in this group, even though they share a similar disulfide topology 
and glycosylation. Further evaluation of their bioactivities with free glucose at high concentrations 
suggested that their antimicrobial mechanisms might be both glycocin- and species-specific. These 
glycocins with distinct features significantly broaden our knowledge and may lead to the discovery 




In Chapter 4, a novel Class IV lanthipeptide was discovered by the same method as I described in 
Chapter 3. Lanthipeptides (lanthionine-containing peptides) constitute a major family RiPPs which 
have thioether crosslinks as their signature structural feature. Although most lanthipeptides exhibit 
antimicrobial bioactivity, other bioactivities such as antifungal (37), morphogenetic (38, 39), 
antiviral (40), antinociceptive (41), and antiallodynic functions (42) were also discovered. Based 
on the characteristics of lanthipeptide synthases, lanthipeptides were subdivided into four classes 
(Class I-Class IV). While extensive studies have been carried out for Class I and Class II 
lanthipeptides, there is little knowledge for Class III and Class IV lanthipeptides. Particularly, only 
a few Class IV lanthipeptides have been characterized and they all structurally resemble to 
venezuelin, a prototype Class IV lanthipeptide. In this chapter, I successfully identified a novel 
Class IV lanthipeptide with completely new structure. To further characterize its biosynthesis, the 
post-translational modification was reconstituted in vitro. By analyzing the structure of the 
intermediates of biosynthesis, the lanthipeptide synthase reveal a bi-directional cyclization activity.  
 
Chapter 5 describes the characterization of the biosynthesis of heat stable antifungal factor (HSAF), 
which is a polyketide belonging to polycyclic tetramate macrolactam. Previously Zhao and 
coworkers activated a cryptic polycyclic tetramate macrolactam pathway from Streptomyces 
griseus and proposed a parallel biosynthetic mechanism for this pathway. To further investigate if 
such a parallel biosynthetic mechanism generally exists for other polycyclic tetramate 
macrolactams, I chose the HSAF pathway and carried out multiple gene knockouts in order to 
identify the key intermediates. Three intermediates were successfully isolated and characterized 
by mass spectrometry and NMR, which supports the assumption that the HSAF pathway also has 
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a parallel biosynthetic mechanism. Bioinformatic studies also reveal that such a biosynthetic 
mechanism might generally exist in most of the polycyclic tetramate macrolactam pathways. 
  
Chapter 6 describes some preliminary data about the development of CRISPR-based approaches 
for titratable activation and repression of genes in Streptomyces species. Streptomyces are ideal 
chassis for discovery and overproduction of medically relevant secondary metabolites (43). 
However, the shortage of genetic engineering tools in streptomyces largely restricted their practical 
applications. In this chapter, I demonstrated the activity of CRISPR-dCas9 in Streptomyces 
lividans 66 and Streptomyces albus J1074. By attaching the RNA polymerase omega factor 
(RNAP-ω) to the C-terminal of Cas9 protein, the fusion protein was able to increase the gene 
expression level through targeting the corresponding promoter region. Of note, the titratable 
repression of target genes was supposed to be achieved by using an inducible promoter to tune the 
expression of gRNA. However, the leakage of gRNA expression led to significant target repression 
without any induction and thus a limited tunable range. Therefore, systematic optimization to fine-










Figure 1.1. Overview of the workflow for a modern natural product discovery strategy. BGCs are 
first identified from genomic sequences by bioinformatics tools and then activated by different 
synthetic biology strategies. Products are characterized by high-throughput methods and the data 













Figure 1.2. Representative methods for direct cloning of BGCs. (a) TAR and RecET mediated in 



















Figure 1.3. Representative methods for refactoring of BGCs. (a) mCRISTAR; (b) Plug-and-play 
Golden Gate assembly based pathway refactoring; (c) Artificial gene operon assembly system 





















1. Newman DJ & Cragg GM (2016) Natural products as sources of new drugs from 1981 to 
2014. J Nat Prod 79(3):629-661. 
2. Demain AL & Sanchez S (2009) Microbial drug discovery: 80 years of progress. J 
Antibiot 62(1):5-16. 
3. Rutledge PJ & Challis GL (2015) Discovery of microbial natural products by activation 
of silent biosynthetic gene clusters. Nat Rev Microbiol 13(8):509-523. 
4. Li JWH & Vederas JC (2009) Drug discovery and natural products: end of an era or an 
endless frontier? Science 325(5937):161-165. 
5. Bentley SD, et al. (2002) Complete genome sequence of the model actinomycete 
Streptomyces coelicolor A3(2). Nature 417(6885):141-147. 
6. Ikeda H, et al. (2003) Complete genome sequence and comparative analysis of the 
industrial microorganism Streptomyces avermitilis. Nat Biotechnol 21(5):526-531. 
7. Ren HQ, Wang B, & Zhao HM (2017) Breaking the silence: new strategies for 
discovering novel natural products. Curr Opin Biotech 48:21-27. 
8. Smanski MJ, et al. (2016) Synthetic biology to access and expand nature's chemical 
diversity. Nat Rev Microbiol 14(3):135-149. 
9. Hu SB, et al. (2016) "Cre/loxP plus BAC": a strategy for direct cloning of large DNA 
fragment and its applications in Photorhabdus luminescens and Agrobacterium 
tumefaciens. Sci Rep 6:29087. 
10. Dai RX, Zhang B, Zhao GP, & Ding XM (2015) Site-specific recombination for cloning 
of large DNA fragments in vitro. Eng Life Sci 15(6):655-659. 
11. Jiang WJ & Zhu TF (2016) Targeted isolation and cloning of 100-kb microbial genomic 
sequences by Cas9-assisted targeting of chromosome segments. Nat Protoc 11(5):960-
975. 
12. Jiang WJ, et al. (2015) Cas9-assisted targeting of chromosome segments CATCH enables 
one-step targeted cloning of large gene clusters. Nat Commun 6. 
13. Fu J, et al. (2012) Full-length RecE enhances linear-linear homologous recombination 
and facilitates direct cloning for bioprospecting. Nat Biotechnol 30(5):440. 
14. Yamanaka K, et al. (2014) Direct cloning and refactoring of a silent lipopeptide 
biosynthetic gene cluster yields the antibiotic taromycin A. P Natl Acad Sci USA 
111(5):1957-1962. 
15. Li L, Jiang WH, & Lu YH (2017) New strategies and approaches for engineering 
biosynthetic gene clusters of microbial natural products. Biotechnol Adv 35(8):936-949. 
16. Chang FY, Ternei MA, Calle PY, & Brady SF (2013) Discovery and synthetic 
refactoring of tryptophan dimer gene clusters from the environment. J Am Chem Soc 
135(47):17906-17912. 
17. Kuthning A, Mosker E, & Sussmuth RD (2015) Engineering the heterologous expression 
of lanthipeptides in Escherichia coli by multigene assembly. Appl Microbiol Biot 
99(15):6351-6361. 
18. McClerren AL, et al. (2006) Discovery and in vitro biosynthesis of haloduracin, a two-
component lantibiotic. P Natl Acad Sci USA 103(46):17243-17248. 
19. Gibson DG, et al. (2009) Enzymatic assembly of DNA molecules up to several hundred 
kilobases. Nat Methods 6(5):343-U341. 
18 
 
20. Engler C, Gruetzner R, Kandzia R, & Marillonnet S (2009) Golden Gate shuffling: a one-
pot DNA shuffling method based on type IIs restriction enzymes. Plos One 4(5):e5553. 
21. Shao Z, Zhao H, & Zhao H (2009) DNA assembler, an in vivo genetic method for rapid 
construction of biochemical pathways. Nucleic Acids Res 37(2):e16. 
22. Shao ZY & Zhao HM (2012) DNA assembler: a synthetic biology tool for characterizing 
and engineering natural product gene clusters. Method Enzymol 517:203-224. 
23. Basitta P, et al. (2017) AGOS: a plug-and-play method for the assembly of artificial gene 
operons into functional biosynthetic gene clusters. ACS Synth Biol 6(5):817-825. 
24. Montiel D, Kang HS, Chang FY, Charlop-Powers Z, & Brady SF (2015) Yeast 
homologous recombination-based promoter engineering for the activation of silent 
natural product biosynthetic gene clusters. P Natl Acad Sci USA 112(29):8953-8958. 
25. Kang HS, Charlop-Powers Z, & Brady SF (2016) Multiplexed CRISPR/Cas9-and TAR-
mediated promoter engineering of natural product biosynthetic gene clusters in yeast. 
ACS Synth Biol 5(9):1002-1010. 
26. Shao ZY & Zhao HM (2013) Construction and engineering of large biochemical 
pathways via DNA assembler. Methods Mol Biol 1073:85-106. 
27. Luo YZ, et al. (2013) Activation and characterization of a cryptic polycyclic tetramate 
macrolactam biosynthetic gene cluster. Nat Commun 4. 
28. Harvey CJB, et al. (2018) HEx: A heterologous expression platform for the discovery of 
fungal natural products. Sci Adv 4(4):eaar5459. 
29. Freestone TS, Ju KS, Wang B, & Zhao HM (2017) Discovery of a phosphonoacetic acid 
derived natural product by pathway refactoring. ACS Synth Biol 6(2):217-223. 
30. Smanski MJ, et al. (2014) Functional optimization of gene clusters by combinatorial 
design and assembly. Nat Biotechnol 32(12):1241-U1104. 
31. Arnison PG, et al. (2013) Ribosomally synthesized and post-translationally modified 
peptide natural products: overview and recommendations for a universal nomenclature. 
Nat Prod Rep 30(12):1568-1568. 
32. Dang T & Suesmuth RD (2017) Bioactive peptide natural products as lead structures for 
medicinal use. Accounts Chem Res 50(7):1566-1576. 
33. Gomes ES, Schuch V, & Lemos EGD (2013) Biotechnology of polyketides: New breath 
of life for the novel antibiotic genetic pathways discovery through metagenomics. Braz J 
Microbiol 44(4):1007-1034. 
34. Steenbergen JN, Alder J, Thorne GM, & Tally FP (2005) Daptomycin: a lipopeptide 
antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemoth 
55(3):283-288. 
35. Chopra I & Roberts M (2001) Tetracycline antibiotics: mode of action, applications, 
molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol R 
65(2):232-260. 
36. Demain AL & Vaishnav P (2011) Natural products for cancer chemotherapy. Microb 
Biotechnol 4(6):687-699. 
37. Mohr KI, et al. (2015) Pinensins: the first antifungal lantibiotics. Angew Chem Int Edit 
54(38):11254-11258. 
38. Kodani S, et al. (2004) The SapB morphogen is a lantibiotic-like peptide derived from 




39. Kodani S, Lodato MA, Durrant MC, Picart F, & Willey JM (2005) SapT, a lanthionine-
containing peptide involved in aerial hyphae formation in the streptomycetes. Mol 
Microbiol 58(5):1368-1380. 
40. Ferir G, et al. (2013) The Lantibiotic peptide labyrinthopeptin A1 demonstrates broad 
anti-HIV and anti-HSV activity with potential for microbicidal applications. Plos One 
8(5). 
41. Iorio M, et al. (2014) A glycosylated, labionin-containing lanthipeptide with marked 
antinociceptive activity. ACS Chem Biol 9(2):398-404. 
42. Meindl K, et al. (2010) Labyrinthopeptins: a new class of carbacyclic lantibiotics. Angew 
Chem Int Edit 49(6):1151-1154. 
43. Liu R, Deng ZX, & Liu TG (2018) Streptomyces species: ideal chassis for natural 

























Chapter 2: A Plug-and-Play Pathway Refactoring Workflow for Natural 
Product Research in Escherichia coli and Saccharomyces cerevisiae 
2.1 Introduction 
Natural products are an indispensable source for drug discovery (1). However, due to the ever-
increasing rediscovery rate of natural products by traditional methods, an important approach to 
expand the natural product library for screening new drug candidates is combinatorial biosynthesis 
(2). Thanks to the great efforts on natural product research in the past decades, biosynthetic genes 
with various functions have been continuously characterized. Moreover, the advances in next 
generation sequencing and bioinformatics have enabled rapid prediction of numerous biosynthetic 
gene clusters (BGCs) with the potential to generate novel natural products (3, 4). Nevertheless, 
most studies in combinatorial biosynthesis are limited to only a small fraction of all possible 
combinations, mainly due to the lack of a high-throughput pathway refactoring method (5). 
Besides combinatorial biosynthesis, another intriguing part of natural product research is the 
investigation of biosynthetic mechanisms, which usually requires gene deletion in a BGC. 
However, gene deletion by constructing pathway variants through existing DNA assembly 
methods usually affects the context of other genes, resulting in repetitive cloning work. Therefore, 
it is highly desirable to develop a fast, high-throughput and flexible pathway refactoring method 
for natural product research. 
 
Pathway refactoring can be technically accomplished through DNA assembly. Golden Gate 
reaction is a DNA assembly method based on the activity of Type IIs restriction enzymes, which 
cut outside their recognition sites and generate single-strand DNA overhangs (6). When designed 
appropriately, the overhangs can guide the corresponding DNA fragments to be ligated in a 
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designated order by a DNA ligase. Previously, we optimized the condition of Golden Gate 
assembly with high and consistent fidelity (above 95%) and successfully applied it for high-
throughput synthesis of transcription activator-like effectors (TALEs) (7). In this work, we 
extended this strategy to establish a scalable pathway refactoring workflow. Briefly, multiple 
helper plasmids are constructed with well characterized promoters and terminators between which 
biosynthetic genes can be inserted. The constructed cassettes in the helper plasmid can then be 
assembled in a defined order with the help of 4 bp overhangs. Spacer plasmids, which share the 
same 4 bp overhangs with their corresponding helper plasmids but only encode a 20 bp random 
DNA sequence are also constructed and help the refactoring workflow adapt to pathways with 
different number of genes. We employed this workflow to refactor the zeaxanthin biosynthetic 
pathway and achieved high fidelity. Because of the highly modularized design, the gene deletion 
and replacement can also be realized by appropriately using the spacer plasmids. As proof of 
concept, 96 functional pathways for combinatorial carotenoid biosynthesis were successfully built 
using this workflow. 
 
2.2 Results and Discussion  
2.2.1 Design of the Plug-and-Play Pathway Refactoring Workflow 
As shown in Figure 2.1, the workflow consists of two tiers of Golden Gate reaction, which are 
catalyzed by BbsI (1st tier) and BsaI (2nd tier) respectively. The biosynthetic gene can be either 
synthesized or PCR amplified with two BbsI cleavage sites at both ends, which help in generating 
the general overhangs AATG (at the side of start codon) and CGGT (at the side of stop codon) 
respectively. Other BbsI and BsaI cleavage sites in the biosynthetic gene need to be removed at 
the same time through silent mutations. The same BbsI cleavage sites and the corresponding 
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overhangs also exist on the helper plasmid, flanking a counter-selection marker (ccdB). Those BbsI 
cleavage sites on the helper plasmid are also flanked by a promoter and a terminator (Figure 2.1A).  
In the 1st tier BbsI catalyzed Golden Gate reaction, the ccdB marker on the helper plasmid is 
replaced by the biosynthetic gene, resulting in an expression cassette. In the overhang AATG 
between the promoter and the biosynthetic gene, the first “A” comes from the last nucleotide of 
the promoter followed by the start codon “ATG” of the biosynthetic gene. This design allows the 
seamless connection of the promoter and the biosynthetic gene.  
 
After the 1st tier reaction, all the helper plasmids containing expression cassettes can be ligated 
together by their unique overhangs generated by BsaI in the 2nd tier reaction. However, as the 
number of biosynthetic genes varies from one BGC to another, gaps can appear once the number 
of biosynthetic genes is less than the number of helper plasmids (Figure 2.1B). Therefore, another 
set of plasmids called “spacer plasmids” are included in the system which have the same overhangs 
with their corresponding helper plasmids, but only a random 20 bp DNA sequence in the middle. 
When the helper plasmid is not used in the 1st tier reaction, the corresponding spacer plasmid can 
be used to “fill the gap” in that position (Figure 2.1B). As a result, the 4 bp overhangs (ATGG and 
AGCG) flanking the ccdB marker on the receiver plasmid are not affected and the same receiver 
plasmid can be used for assembling pathways with various number of expression cassettes. 
 
2.2.2 Refactoring of the Zeaxanthin Biosynthetic Pathway Using S. cerevisiae Promoters 
and Terminators 
As proof of concept, we applied this workflow to refactor the zeaxanthin biosynthetic pathway in 
S. cerevisiae (8). Nine helper plasmids were built using the promoters and terminators from S. 
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cerevisiae and the corresponding spacer plasmids were also built with the 20 bp random sequences 
designed by R2oDNA (Table 1) (9). We first checked the fidelity of the 1st tier reaction by blue-
white screening. The lacZ cassette was cloned into one of the helper plasmids and the reaction 
mixture was transformed into NEB10-beta and spread on an LB+Amp plate with 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (X-gal) and isopropyl β-D-1-thiogalactopyranoside 
(IPTG). After overnight incubation, all the colonies on plate were blue, indicating the fidelity of 
the 1st tier reaction was 100% (Figure 2.2). By using the same reaction condition, all of the five 
genes from the zeaxanthin pathway were cloned into different S. cerevisiae helper plasmids 
respectively and 6 colonies were picked from each reaction. The plasmids isolated from these 
clones were digested by BsaI and all of them showed the correct digestion patterns (Figure 2.3A). 
Then the 5 plasmids with the corresponding expression cassettes were mixed with the other 4 
spacer plasmids and the receiver plasmid for the 2nd tier Golden Gate reaction. After transformation 
into NEB10-beta and overnight incubation, constructs isolated from all 20 transformants showed 
the expected digestion patterns, indicating 100% assembly fidelity (Figure 2.3C).  
 
Since both the 1st and 2nd tier Golden Gate reactions showed very high fidelity, we hypothesized 
that polyclonal plasmids could also be used for cloning and expression, which would save the time 
for colony growth on the plate and the labor for colony picking. As a polyclonal plasmid can be 
obtained from either the 1st or 2nd tier reaction, there are four scenarios to obtain the final construct 
(I: monoclonal-monoclonal; II: monoclonal-polyclonal; III: polyclonal-monoclonal; IV: 
polyclonal-polyclonal). Polyclonal plasmids from the 1st tier reaction were digested and showed 
no significant difference from their monoclonal counterparts (Figure 2.3B), and these plasmids 
were used for 2nd tier reaction for scenarios III and IV. In scenario III, 20 colonies from the 2nd tier 
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reaction were picked for plasmid isolation and digestion, 19 out of 20 showed a correct pattern 
(Figure 2.3D). In scenarios II and IV, polyclonal plasmids from the 2nd tier reaction were also 
checked by restriction digestion and no significant difference from the monoclonal one can be 
observed (Figure 2.3E). The final constructs from scenario I to scenario IV were transformed into 
S. cerevisiae CEN.PK2-1C for expression. Cells were extracted by acetone and analyzed by HPLC. 
All samples showed peaks at 430 nm with the same retention time as the zeaxanthin standard, 
which confirmed the production of zeaxanthin (Figure 2.3F-G). By using polyclonal cultures, the 
workflow can be finished in two days, which is suitable for quick check of the pathway’s function. 
However, we recommend using monoclonal cultures for quantitative analysis of the pathway’s 
function, which only requires some additional waiting time (1 or 2 overnight) for colony growth.  
 
2.2.3 Construction of Various Zeaxanthin Pathways with Gene Deletions Using Spacer 
Plasmids 
Because of its high modularity, this workflow also enables researchers to delete genes in the final 
construct for biosynthetic mechanistic studies with minimal cloning effort. Because every 
expression cassette should have the same overhangs that are generated by BsaI with the 
corresponding spacer plasmid, inclusion/deletion of a gene can be readily accomplished by using 
either the expression cassette or the corresponding spacer plasmid in the 2nd tier reaction and no 
repetitive cloning effort in the 1st tier is needed. As proof of concept, the same expression cassettes 
for the construction of the zeaxanthin pathway were used to build pathways producing phytoene, 
lycopene and β-carotene, which are intermediates in the zeaxanthin biosynthesis (10). The final 
constructs were again transformed into CEN.PK2-1C and extracted by acetone. The expected 
colors associated with these products were observed for all the three samples (Figure 2.4C). The 
25 
 
samples were further analyzed with HPLC and LC/MS and the production of phytoene 1, lycopene 
2 and β-carotene 3 was verified (Figure 2.4 and Figure 2.6). 
 
2.2.4 Construction of Pathways for Combinatorial Carotenoid Biosynthesis in E. coli 
Because the overhangs generated by BsaI are independent from the sequence of the biosynthetic 
gene, every gene in the final construct can be easily replaced by another gene sharing the same 
helper plasmid. As a demonstration, two C30 carotenoid pathways with only one gene difference 
were selected (11) (Figure 2.5A). CrtM and CrtN produce the intermediate diapolycopene shared 
by those two pathways and then CrtA or CrtOx adds a ketone group (or a hydroxyl group) at 
different positions (12, 13). As all the four enzymes showed little activity in S. cerevisiae, another 
set of helper plasmids with T7 promoters and terminators (four in total) was built for the expression 
in E. coli. The final constructs were transformed into BL21(DE3) for expression and the yellow, 
orange and red colors were observed in the corresponding crude extracts (Figure 2.5C). The crude 
extracts were again analyzed by the HPLC and LC/MS. The diapolycopene 4 was observed from 
CrtM+CrtN at 430 nm. The expected product compounds 5 and 6 were verified from 
CrtM+CrtN+CrtA by LC/MS while compounds 7, 8 and 9 were verified from CrtM+CrtN+CrtOx 
by LC/MS as well (Figure 2.5 and Figure 2.6). 
 
Finally, to investigate whether the plug-and-play workflow has the potential to be scaled up and 
applied in combinatorial biosynthesis, a total of 96 pathways were created for the biosynthesis of 
carotenoids. Carotenoid biosynthesis can be split into three steps: a) backbone synthesis, b) 
desaturation, and c) cyclization or other modification (11, 14). Taking the biosynthesis of β-
carotene as an example, the CrtE and CrtB first catalyze the formation of the C40 backbone 
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phytoene, then the double bonds are introduced by CrtI, and finally the two ring structures are 
formed by CrtY. Accordingly, we collected 15 carotenoid biosynthetic genes and mutants and 
divided them into 3 groups. The backbone synthases group (group 1) includes four subgroups 
which can produce carotenoid backbones ranging from C30 to C50 (15, 16). The desaturases group 
(group 2) contains wild type C40 desaturase CrtI and its two mutants and wild type C30 desaturase 
CrtN (10). The cyclases and others group (group 3) consists of six enzymes which can catalyze 
different cyclization and oxidation reactions (10, 17) (Figure 2.7A). As the longest pathway 
consists of four genes (two from group 1, one from group 2 and one from group 3), the 4 helper 
plasmids that we built for the expression in E. coli should be sufficient for constructing all of the 
96 combinations. Genes from group 1 were assigned to either helper plasmid 1 or helper plasmid 
2, while genes from group 2 and 3 were assigned to helper plasmids 3 and 4 respectively. 
Successful assembly of the 96 constructs were confirmed using restriction digestion, and the 
plasmids were transformed into BL21(DE3) for carotenoid production. Carotenoids with different 
colors were generated after overnight induction by IPTG (Figure 2.7B). 
 
2.3 Conclusion  
In this work we have developed a pathway refactoring workflow based on hierarchical Golden 
Gate assembly. Two sets of helper plasmids and one set of spacer plasmids with standardized 4 bp 
overhangs were constructed, which enabled the addition, deletion and exchange of expression 
cassettes in the final construct with minimal cloning effort. By using the optimized condition of 
Golden Gate assembly, high-throughput pathway refactoring was accomplished and demonstrated 




Prior to this work, a few Golden Gate reaction based multigene assembly systems have been 
developed, such as the GoldenBraid and the modular cloning (MoClo) system (18, 19). Among all 
these systems, the most representative one is the MoClo and currently there are multiple toolkits 
and part libraries available to enable its application in various hosts, such as E. coli and S. 
cerevisiae (20, 21). By its delicate design, MoClo enables researchers to assemble multigene 
constructs with very high flexibility, as all the parts, such as promoters and terminators, are 
modularized and free to be changed. But in the natural product research, since the discovery of 
new natural products and the study of biosynthetic mechanisms are usually the focuses, it is 
unnecessary to find out the best combination of promoters for the BGC and in most cases strong 
promoters are arbitrarily chosen. Therefore, we include all the elements that are necessary for gene 
expression in our helper plasmids. Since only the target gene and the helper plasmid are needed 
for the 1st tier reaction, potentially repetitive work to add the same parts, such as promoters and 
terminators, are avoided, which makes the process friendlier for high-throughput automation-
based natural product researches, even though the flexibility is more or less affected. In addition, 
MoClo has also designed many end-linkers and destination vectors to help its users add or delete 
genes at both ends in their constructs, but it is unable to delete the gene in the middle without 
including the selectable marker. However, in the study of biosynthetic mechanisms, researchers 
usually do not know the gene functions in the BGC. As a result, genes at any positions of their 
construct might need to be deleted. Thus, we include the spacer plasmids in our workflow, which 
not only makes the gene deletion become easier, but also reduces the total number of the working 
plasmids (helper plasmids, receiver plasmids, etc.) that are needed in the system. Overall, our 





In addition to the applications for biosynthetic mechanism investigation and combinatorial 
biosynthesis as demonstrated in this work, another potential application of this workflow would 
be the activation of silent BGCs (22), which is currently underway in our laboratory. In summary, 
this pathway refactoring workflow can serve as a powerful tool for the natural product research in 
the future. 
 
2.4 Materials and Methods 
2.4.1 Strains, Media and Cell Cultivation 
All chemicals were purchased from Sigma-Aldrich or ThermoFisher Scientific. E. coli NEB® 10-
beta (New England Biolabs, Ipswich, MA) was used for DNA manipulation. Plasmids containing 
ccdB marker are propagated in E. coli DB3.1 (gyrA462 endA1 ∆(sr1-recA) mcrB mrr hsdS20 
glnV44 (=supE44) ara14 galK2 lacY1 proA2 rpsL20 xyl5 leuB6 mtl1). S. cerevisiae strain 
CEN.PK2-1C (MATa ura3−52 trp1−289 leu2−3,112 his3Δ1 MAL2−8C SUC2) (EUROSCARF) 
and E. coli BL21(DE3) (Cell Media Facility, University of Illinois at Urbana−Champaign, Urbana, 
IL) were used for carotenoid production. E. coli was cultured in Lysogeny broth (LB) 
(ThermoFisher Scientific, Waltham, MA) containing appropriate antibiotics at 37 °C and 250 rpm 
unless specified otherwise. S. cerevisiae was cultured in synthetic complete medium (SC-URA) 
consisting of 0.17% Difco yeast nitrogen base without amino acids, 0.5% ammonium sulfate, and 
0.083% amino acid drop out mixture without uracil (MP Biomedicals, Solon, OH) supplemented 
with 2% glucose was used for DNA homologous recombination and zeaxanthin fermentation. The 
plasmids containing S. cerevisiae promoters and terminators and the genes (crtE, crtB, crtI, crtY, 
crtZ) were described elsewhere (8). The plasmids containing other carotenoid biosynthetic genes 
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were gifts from Frances Arnold at the California Institute of Technology and Claudia Schmidt-
Dannert at the University of Minnesota. 
 
2.4.2 1st Tier Golden Gate Reaction 
100 ng helper plasmid was mixed with an insert in 1:3 molar ratio. The reaction condition was as 
follows: a 20 μL reaction system contained 2 μL 10x Tango buffer (ThermoFisher Scientific, 
Waltham, MA), 1 μL 10 mM dithiothreitol (DTT), 1 μL 10 mM adenosine triphosphate (ATP), 1 
μL FastDigest BbsI (ThermoFisher Scientific, Waltham, MA), 0.5 μL T7 ligase (Enzymatics, 
Beverley, MA), and ddH2O to 20 μL. The following temperature cycles were set up: 6 cycles of 5 
min at 37 ℃ and 5 min at 21 ℃. Then the reaction mix was treated by Plasmid-Safe-ATP-
Dependent DNase (Epicentre, Madison, WI) by adding 0.25 μL enzyme and 1 μL 25 mM ATP 
and then incubating at 37 ℃ for 30 min. 10 μL reaction mix was then transformed into 100 μL 
NEB® 10-beta competent cell by standard heat-shock transformation. After recovery in 1 mL LB 
at 37 ℃ for 1 h, 5 μL was inoculated into 5 mL LB with 100 μg/mL ampicillin for polyclonal 
plasmid isolation or spread on LB+Amp plate and incubate overnight at 37 ℃. Single colony was 
inoculated into 5 mL LB liquid culture with 100 μg/mL ampicillin next day for monoclonal 
plasmid isolation. Plasmids were isolated using QIAGEN Plasmid Mini Kit (QIAGEN, 
Germantown, MD). The maps of the helper plasmids used in this work are shown in Figure 2.8 
and Figure 2.9. 
 
2.4.3 2nd Tier Golden Gate Reaction 
100 ng receiver plasmid (~0.035 nmol) was mixed with the same molar amount of helper plasmids 
with corresponding inserts cloned in and the appropriate spacer plasmids. The reaction condition 
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was as follows: a 20 μL reaction system contained 2 μL 10x T4 DNA Ligase Reaction Buffer 
(New England Biolabs, Ipswich, MA), 0.8 μL BsaI (New England Biolabs, Ipswich, MA), 0.2 μL 
T4 DNA Ligase (M0202T, New England Biolabs, Ipswich, MA), and ddH2O to 20 μL. The 
following temperature cycles were set up: 5 min at 37 ℃, 30 cycles of 5 min at 37 ℃ and 10 min 
at 16 ℃, 30 min at 16 ℃, 45 min at 37 ℃ and 5 min at 80 ℃. The reaction was then treated by 
Plasmid-Safe-ATP-Dependent DNase (Epicentre, Madison, WI) and transformed into 100 μL 
NEB® 10-beta competent cell, which was similar to the 1st tier Golden Gate reaction. Monoclonal 
and polyclonal plasmids were isolated by the same method that described in the 1st tier Golden 
Gate reaction. Plasmids were isolated using QIAGEN Plasmid Mini Kit (QIAGEN, Germantown, 
MD). The maps and sequences of the spacer and receiver plasmids used in this work are available 
in Figures 2.10-2.12. 
 
2.4.4 Design of the Spacer Plasmid Inserts 
All insert sequences were designed using R2oDNA (http://www.r2odna.com/) with the following 
criteria: GC content of 60%; no start codons, common multiple cloning sites (MCS), or assembly 
restriction sites; no bacterial promoter-like sequences; and no similar sequences within E. coli and 
S. cerevisiae genome. Detailed sequences of 18 unique inserts utilized in this study are listed in 
Table 1. 
 
2.4.5 Functional Analysis of the Assembled Pathways 
For carotenoid pathways expressed in S. cerevisiae, cell pellets were harvested from either 50 mL 
(for analysis of zeaxanthin) or 500 mL (for analysis of phytoene, lycopene and β-carotene) Sc-Ura 
liquid media after fermentation at 30 ℃ and 250 rpm for 72 h. The extraction was performed as 
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previously described (8). Briefly the cell pellet was resuspended by 50 mL acetone and passed 
through French press at 10,000 psi three times.  
 
Pathways for carotenoid biosynthesis in E. coli was induced by 0.1 mM IPTG when the OD600 
reached 0.6-0.8 and the cell pellets containing the CrtM+CrtN, CrtM+CrtN+CrtA, or 
CrtM+CrtN+CrtOx pathways were harvested from 500 mL LB liquid media after fermentation at 
30 ℃ and 250 rpm for 24 h. The cell pellet was resuspended in 50 mL acetone and vortexed for 1 
min.  
 
After extraction from either S. cerevisiae or E. coli, the supernatant was collected after 
centrifugation and evaporated to dryness. After resuspension in 200 μL THF, 20 μL was analyzed 
on an Agilent 1100 series HPLC with a Photodiode Array (PDA) detector. H2O + 0.1% formic 
acid (solvent A) and acetonitrile + 0.1% formic acid (solvent B) were used as mobile phase and 
different reverse-phase columns were used for different samples. The zeaxanthin containing crude 
extract was loaded onto Kinetex® 2.6 μm EVO C18 100Å 150x2.1 mm column (Phenomenex, 
Torrance, CA) and eluted at 0.2 mL/min with the following gradient: 50% B for 5 min, to 100% 
B in 10 min, hold at 100% B for 10 min and return to 50% B over 10 min. The other samples were 
loaded onto Kinetex® 5 μm EVO C18 100Å 250x4.6 mm column (Phenomenex, Torrance, CA) 
and eluted at 1 mL/min with the following gradient: 70% B for 15 min, to 100% B in 60 min, hold 
at 100% B for 30 min and return to 70% over 15 min. The same condition was used for the analysis 
of carotenoids by LC/MS (Agilent). Mass spectra were acquired in ultra scan mode using 
atmospheric pressure chemical ionization with positive polarity. The MS system (Agilent 1100 
32 
 
LC/MSD Trap XCT Plus) was operated using a drying temperature of 350 °C, a nebulizer pressure 
of 35 psi, a drying gas flow of 8.5 L/min, and a capillary voltage of 4500 V.  
 
The 96 combinatorial pathways for carotenoid biosynthesis in E. coli were similarly induced by 
0.1 mM IPTG and fermented at 30 ℃ and 250 rpm for 24 h. Then 1 mL culture was taken from 5 
mL culture for each pathway and placed into the corresponding position in a 96 deep well plate. 

















2.5 Figures and Table 
Figure 2.1. Scheme of the plug-and-play pathway refactoring workflow. (A) The 1st tier Golden 
Gate reaction. The gene is either synthesized or PCR amplified with BbsI cleavage sites at both 
ends and cloned into a helper plasmid through BbsI catalyzed Golden Gate reaction. (B) The 2nd 
tier Golden Gate reaction. Helper plasmids harboring the corresponding genes are mixed with the 
appropriate spacer plasmids and the receiver plasmid and assembled into the final construct 
through BsaI catalyzed Golden Gate reaction. All helper plasmids and spacer plasmids share the 
pUC19 backbone, while the receiver plasmid has either a pET28a backbone (for expression in E. 
coli) or pRS416 backbone with the ampicillin resistance gene replaced by the kanamycin resistance 



























Figure 2.3. (A) The fidelity of the 1st tier reaction (monoclonal) checked by restriction digestion 
(expected band sizes: CrtE-Helper 1: 1.7 kb + 1.7 kb; CrtB-Helper 3: 2.2 kb + 1.7 kb; CrtI-Helper 
5: 2.6 kb + 1.7 kb; CrtY-Helper 7: 1.9 kb+ 1.7 kb; CrtZ-Helper 9: 1.7 kb + 1.6 kb). (B) The fidelity 
of the 1st tier reaction (polyclonal) checked by restriction digestion. All the plasmids obtained from 
the 1st tier reactions were double-checked by Sanger sequencing. (C-E) The fidelity of the 2nd tier 
reaction (scenarios I-IV) checked by restriction digestion (expected band sizes: 5.7 kb + 4.3 kb + 
2.7 kb + 1.6 kb). (F) The crude extract of zeaxanthin producing CEN.PK2-1C. (G) HPLC profile 










Figure 2.4. Analysis of the zeaxanthin producing pathway variants with gene deletion expressed 
in S. cerevisiae. (A) Pathways refactored for analysis. (B) Structures of carotenoids expected to be 
produced. (C) HPLC-UV traces. (D) UV absorption of the corresponding peaks. MS data is shown 









Figure 2.5. Analysis of the C30 carotenoid producing pathways expressed in E. coli. (A) Pathways 
refactored for analysis. (B) Structures of carotenoids expected to be produced. (C) HPLC-UV 
traces. (D) UV absorption of the corresponding peaks. MS data is shown in Figure 2.6. This figure 











Figure 2.6. The HPLC profile and corresponding extracted ion chromatography obtained from 
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Figure 2.7. (A) The genes included in the 96 combinatorial pathways for carotenoid 
biosynthesis. Negative control (BL21(DE3) with empty pET28a plasmid) at the right side. (B) 

















Figure 2.8. Plasmid designs and sequences of the S. cerevisiae helper plasmids. 
 
























Figure 2.8 Continue 
pUC19 BbsI ccdB Helper 3 PDCp TEF1t GCTC CGGT 
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Figure 2.9. The plasmid design and sequence of the T7 helper plasmid-1. Other T7 helper plasmids 




























Figure 2.10. The plasmid design and sequence of the spacer-1. Other spacer plasmids share the 
same design and sequence except for the 20 bp spacer sequences and 4 bp overhangs, which are 
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Table 2.1. Promoters and terminators used in construction of helper plasmids for expression in S. 
cerevisiae and the corresponding 20 bp spacer sequences with 4 bp overhangs. All of the helper 
plasmids for expression in E. coli use the T7 promoter and terminator and the 4th helper plasmid 
uses the CGGT and AGCG as the 4 bp overhangs. 
 
Position Promoter Terminator 20 bp Spacer Sequence+4 bp Overhangs 
1 TPI1P PGK1t ATGGccgagttcgctggtcacactCCCT 
2 ENO2p GPDt CCCTagacgctgtgcctctcagtaGCTC 
3 PDCp TEF1t GCTCctatcagcgtcactgggtccCGGT 
4 FBA1p HXT7t CGGTggtttcacaggtccctccagGTGC 
5 GPM1p PYK1t GTGCcctatttcaggacgctcggcGACT 
6 HXT7p ADH2t GACTctcgcacctggctgagttacGGAC 
7 TEF2p FBA1t GGACcacagggtcgtattgcctccTCCG 
8 TDH2p ADH1t TCCGcgcctcgtgtgctatccagaCCAG 
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Chapter 3: Rapid Discovery and Characterization of Glycocins Through 
Pathway Refactoring in E. coli 
3.1 Introduction 
Ribosomally synthesized and post-translationally modified peptides (RiPPs) constitute an 
emerging family of natural products with various structural features and bioactivities (1). 
Glycocins (glycosylated bacteriocins) are a group of RiPPs that feature sugar moieties installed on 
serine, threonine, or cysteine residues and two nested disulfide bonds that stabilize their helix-
loop-helix structures. A typical biosynthetic pathway for glycocin involves five genes. The gene 
encoding the precursor peptide is expressed first and the resulting precursor peptide is then 
glycosylated by a glycosyltransferase. Two disulfide oxidoreductases are responsible for forming 
the disulfide bonds, and a bifunctional transporter transfers the peptide outside the cell and 
removes the leader peptide (2). Four groups of glycocins with distinct scaffolds have been 
discovered to date, with the prototypes being glycocin F (GccF-type), sublancin (SunA/ThuA type), 
enterocin 96 (enterocin 96-type), and enterocin F4-9 (enterocin F4-9-type) (2).  
 
Owing to recent advances in next-generation sequencing and bioinformatics, many putative 
glycocin biosynthetic gene clusters (BGCs) have been identified through genome mining. 
However, only six glycocins have been discovered so far: five isolated from native producers and 
one by chemoenzymatic synthesis (2). This dearth of characterized glycocins may be attributed to 
our limited knowledge of glycocins and technical challenges in product isolation from the native 
producers, particularly pathogens and extremophiles. All six known glycocins show antimicrobial 
bioactivities against several Gram-positive pathogens such as Bacillus cereus, Streptococcus 
pyogenes, and Staphylococcus aureus. Particularly, one of them, sublancin, was also active against 
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drug resistant strains such as methicillin–resistant S. aureus (MRSA) and gentamicin–resistant 
Enterococcus faecalis (3-5). Therefore, glycocins appear to be a promising source for drug lead 
discovery (3, 6) and it is desirable to discover novel glycocins.  
 
In this work, we sought to use a synthetic biology approach based on the pathway refactoring 
strategy we previously developed (7) to rapidly discover new glycocins. RODEO (Rapid ORF 
Description and Evaluation Online) (8) a powerful genome mining tool for RiPPs, was used for 
predicting putative glycocin BGCs. According to their distinct features, six of the putative glycocin 
BGCs were chosen for pathway refactoring in Escherichia coli. Four of them successfully 
produced new glycocins, which were named bacillicin CER074, bacillicin BAG2O, geocillicin, 
and listeriocytocin, respectively. Although these glycocin BGCs originated from various species 
and most of them are either pathogens or extremophiles, our synthetic biology strategy involving 
DNA synthesis and pathway refactoring in E. coli has made the glycocin discovery process rapid 
and scalable.  
 
3.2 Results and Discussion 
3.2.1 Design of a Modified Pathway Refactoring Workflow 
Previously we developed a plug-and-play pathway refactoring workflow for rapid discovery of 
natural products (7). This workflow consists of two-step Golden Gate reactions that first convert 
biosynthetic genes into individual expression cassettes and then assemble these expression 
cassettes into one plasmid. In this work, we adapted this workflow for discovery of new glycocins 
(Figure 3.1). Briefly, the target glycocin BGC is first partially refactored, which involves only the 
peptide precursor gene and the glycosyltransferase gene that are required to generate a 
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glycosylated intermediate (first tier) (9). If a compound corresponding to the expected intermediate 
is detected, the corresponding BGC will then be fully refactored to generate the final product 
(second tier). E. coli BL21(DE3) is used as a heterologous expression host and the BGC genes are 
codon optimized for E. coli and obtained through DNA synthesis. For the refactored partial 
glycocin BGC, after overnight culture in 1 mL media under various temperatures, the resulting 
cell pellets are obtained by centrifugation and homogenized in an ultrasonic bath. For the 
refactored full glycocin BGC, supernatants instead of cell pellets were used for next step analysis. 
Both the supernatants and the cell lysates are desalted and analyzed by MALDI-MS (Matrix 
Assisted Laser Desorption/Ionization-Mass Spectrometry). While this workflow is designed for 
the discovery of glycocins, it’s also potentially applicable for high-throughput discovery of other 
RiPP families in the future.  
 
3.2.2 Refactoring of Glycocin BGCs for Heterologous Expression in E. coli 
Putative glycocin BGCs were predicted by RODEO. The amino acid sequence of 
glycosyltransferase for sublancin (SunS) was used as the query for BLAST and the top 5000 hits 
were used as the input for RODEO, which analyzed the neighboring genes of each input gene in 
batch through comparison against the Pfam pHMM database. All putative glycosyltransferases 
with their neighboring genes were then filtered by the typical features of the glycocin BGCs as 
described in the Materials and Methods. A sequence similarity network was then generated for the 
putative precursor peptides and six BGC candidates for refactoring were mainly chosen from 
different groups in this network (Figure 3.2A). Two out of the six glycocin BGCs which according 
to the sequence of the precursor peptide belong to the same group as the BGC from Bacillus 
megaterium BHG1.1, were chosen because of their extremophile origin (thermophilic strain, 
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Geobacillus sp. 8 and alkaliphilic strain, Bacillus sp. JCM19047), which may offer better stabilities 
under certain conditions for their future studies and/or applications (Figure 3.2 and Figure 3.3) 
(10-14). 
 
The first tier pathway refactoring was performed as indicated in Figure 3.1B. Both the precursor 
peptide and glycosyltransferase were expressed as individual expression cassettes with T7 
promoter and T7 terminator.  After the first tier pathway refactoring process, three out of the six 
partial glycocin BGCs expressed in E. coli generated peaks in the MALDI-TOF mass spectrum 
with molecular weights corresponding to the monoglycosylated precursor peptides (Figure 3.4A). 
Based on the mass increase (162 Da), all the installed sugars were hexoses. The partial glycocin 
BGC from Listeria monocytogenes generated a new peak in the mass spectrum consistent with a 
diglycosylated precursor peptide with an N-terminal truncation. To confirm this result, we 
introduced site-specific mutations (K7A and M8A) at the putative cleavage sites on its precursor 
peptide and coexpressed the mutant precursor gene with the glycosyltransferase (Figure 3.2B). 
The expected full length mutant precursor peptide with two hexoses installed was indeed observed 
in the MALDI-TOF mass spectrum (Figure 3.4B). Given the successful glycosylations, all four 
glycocin BGCs were then fully refactored with every biosynthetic gene expressed as individual 
expression cassettes under T7 promoter and T7 terminator (Figure 3.1B).  Of note, for the glycocin 
BGC from Listeria monocytogenes, the mutant precursor peptide gene was used in pathway 
refactoring. New peaks in the mass spectrum corresponding to the glycosylated precursor peptides 
with their leader peptides removed at the expected sites (Figures 3.3B and 3.6) were observed from 
the desalted supernatants. The resulting four glycocins were named bacillicin CER074, bacillicin 
BAG2O, geocillicin, and listeriocytocin. According to the classification by Norris and coworkers 
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(2), bacillicin CER074, bacillicin BAG2O and geocillicin are SunA/ThuA-type glycocins (10, 13), 
while listeriocytocin is a member of the enterocin 96-type glycocins (Figure 3.2C) (12). 
 
3.2.3 Isolation and Structural Characterization of the Glycocins 
In order to obtain sufficient amounts of glycocins for structure characterization and bioassays (at 
least 40 g for each glycocin for both MS based structural characterization and standard agar 
diffusion assay for bioactivity screening), we further optimized cultivation conditions and purified 
the glycocins through ammonium sulfate precipitation, solid phase extraction, semiprep HPLC, 
and analytical HPLC (Figure 3.7B). The existence of disulfide bonds was first confirmed by an 
iodoacetamide (IAA) assay that demonstrated the absence of free thiols (Figure 3.8) (9). The 
purified glycocins were then digested by chymotrypsin under non-reducing and reducing 
conditions and analyzed by MS. Through assignment of the observed fragments, we concluded 
that all four glycocins shared similar topologies (Figure 3.9). Although the glycosylated residues 
for the three SunA/ThuA type glycocins can be easily assigned to the third cysteine by the results 
of iodoacetamide derivatization and proteolytic digest, MS/MS analysis was necessary to 
determine the glycosylated residue in listeriocytocin. Through sequence alignment, Ser60 in the 
precursor peptide of listeriocytocin was predicted to be glycosylated (Figure 3.3B).  MS/MS data 
unambiguously confirmed this prediction and showed that two successive glycosylations occur on 
Ser60 (Figure 3.10, Figure 3.11, and Figure 3.12). 
 
To further determine the type of hexoses installed in the four glycocins, the glycosylated precursor 
peptides were purified from the corresponding partial BGCs, which resulted in a higher yield than 
refactoring of the full BGCs (Figure 3.5). Notably, in the first tier pathway refactoring, the 
59 
 
precursor genes were cloned into a helper plasmid with an internal N-terminal His-Tag at the 
cloning site (Figure 3.13), which enables the purification of the glycosylated intermediates by 
IMAC (immobilized metal affinity chromatography). These intermediates were then further 
purified by RP-HPLC (reversed-phase high-performance liquid chromatography) and hydrolyzed. 
The sugars were derivatized and analyzed using gas chromatography as described elsewhere (9, 
15). In comparison with various hexose standards, all the installed sugars on these four glycocins 
were shown to be glucoses (Figure 3.7D). Previously, two glycosyltransferases for glycocin 
biosynthesis have been characterized in vitro and exhibited promiscuous activity towards different 
nucleotide sugar substrates (15, 16). Considering that the concentrations of some potential 
nucleotide sugar substrates, such as UDP-N-acetylglucosamine, are much higher than UDP-
glucose in E. coli (17, 18), it appears that the glycosyltransferases under investigation here have a 
preference for UDP-glucose. To further investigate if glycosyltransferases for glycocin 
biosynthesis may exhibit high specificity for their nucleotide sugar substrates in vivo, we also 
coexpressed the precursor peptide of enterocin F4-9 with its glycosyltransferase in BL21(DE3), 
and mass which represents the peptide modified with two N-acetylglucosamines was clearly 
observed on MALDI-MS (Figure 3.14). 
 
All three SunA/ThuA-type glycocins shared similar topology and sugar modification as sublancin 
(Figure 3.9), suggesting these structural features are conserved in this glycocin family. Although 
enterocin 96 was the first discovered enterocin 96-type glycocin, its structure has yet to be 
elucidated (19). Recently the glycosyltransferase of enterocin 96 was reconstituted in vitro and the 
modification was shown to be a disaccharide (16). As we discovered that the listeriocytocin is also 
diglucosylated at the same serine residue predicted to be glycosylated through alignment to 
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enterocin 96, it is very likely that the wild type enterocin 96 shares a similar structure as that 
produced in vitro and the type of sugar modification might be glucose. The diglucosylation might 
be a distinct feature of enterocin 96-type glycocins from other diglycosylated glycocins, such as 
enterocin F4-9 and glycocin F (20, 21). However, listeriocytocin has very distinct structural 
features compared to enterocin 96, such as a much smaller loop size (Figure 3.2C). 
 
3.2.4 Antimicrobial Activity of the Glycocins  
The antimicrobial activity of the four glycocins was probed against a panel of Gram-positive and 
Gram-negative bacteria (Escherichia coli JM109, Pseudomonas aeruginosa PA01, Methicillin-
resistant Streptococcus aureus NRS384/USA300, Vancomycin-resistant Enterococcus faecium 
V583 CB807, Listeria monocytogenes 4b F2365, Bacillus subtilis Δspβ, Bacillus halodurans C-
125 and Bacillus cereus ATCC14579) by a standard agar diffusion assay (Table 1). Although 
listeriocytocin lacked antimicrobial activity toward all organisms tested, bacillicin CER074 and 
bacillicin BAG2O exhibited antimicrobial activity against Bacillus cereus ATCC 14579 (minimal 
inhibitory concentrations: sublancin, 2.5 µM; bacillicin CER074, 0.156 µM; bacillicin BAG2O, 
0.625 µM), and geocillicin also exhibited weak bioactivity (Figure 3.15). Overall, the three newly 
discovered SunA/ThuA-type glycocins have narrower antimicrobial spectrum than sublancin with 
all of them inhibiting the growth of B. cereus ATCC14579, but not other bacilli tested (Figure 3.16 
and Figure 3.17).  
 
As the bioactivity of glycocin F, which is a glycocin decorated with two N-acetylglucosamine 
(GlcNAc) moieties, can be reversed by free GlcNAc (22), we tested if free glucose can have a 
similar effect on the antimicrobial activities of the four new glycocins. While the bioactivities of 
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sublancin and geocillicin could be reversed by free glucose, no significant effects were observed 
for bacillicin CER074 and bacillicin BAG2O, which means these two glycocins might have 
different target(s) from sublancin and geocillicin (Figure 3.5). Previous studies showed that 
sublancin’s activity is mediated by the phosphoenolpyruvate:sugar phosphotransferase system 
(PTS) and  the large mechanosensitive channel of conductance MscL (23, 24). In structure-activity 
relationship (SAR) studies, Arg33 of sublancin was previously shown to be critical for its 
bioactivity against B. subtilis Δspβ and most of the SunA/ThuA-type glycocin are positively 
charged at the corresponding site in a sequence alignment to sublancin (9). However, bioactivity 
was also observed for bacillicin BAG2O that does not contain a corresponding charged residue, 
which may imply that bacillicin BAG2O has a different target(s) from sublancin. Therefore, it 
would be of great interest to further investigate the antimicrobial mechanisms of these new 




In this work, we used a rapid pathway refactoring workflow to discover four novel glycocins from 
various origins, which has significantly expanded the glycocin family. This workflow is potentially 
scalable, which can be very helpful for RiPP discovery in the future. We provide evidence that di-
glycosylation might be a general feature for enterocin 96-type glycocins, and the bioactivity assays 
demonstrate that factors besides the topology and type of glycosylation may affect the bioactivities 




3.4 Materials and Methods 
3.4.1 Materials and Reagents 
All chemicals were purchased from Sigma-Aldrich and Thermo Fisher Scientific. E. coli NEB® 
10-beta was used for DNA manipulation and E. coli BL21(DE3) was used as a host for expression. 
Genes were obtained as gBlocks® from Integrated DNA Technologies. BsaI, T4 DNA ligase and 
other restriction enzymes for checking the assembly of plasmids were obtained from New England 
Biolabs, while the BpiI was obtained from Thermo Fisher Scientific and the T7 DNA ligase was 
obtained from Enzymatics. Plasmids were isolated using QIAGEN Plasmid Mini Kit. Kanamycin 
was used at 50 µg/ml for all E. coli cultures. ZipTip® C18 was purchased from EMD Millipore. 
All sequencing grade peptidases were obtained from Promega.  
 
3.4.2 Genome Mining by RODEO  
The amino acid sequence of SunS (the glycosyltransferase for the biosynthesis of sublancin) was 
used as the query for BLASTP, and the first 5000 hits were used as the input for the analysis by 
RODEO. Each predicted gene cluster was filtered by the existence of all genes which are necessary 
for glycocin biosynthesis (genes encoding SunA-like precursor, SunS-like glycosyltransferase, 
disulfide bond formation protein/thioredoxin, SunT-like transporter). The gene encoding a peptide 
less than 100 aa with at least four cysteines was considered as the putative precursor gene. 
 
3.4.3 Pathway Refactoring Through the Plug-and-Play Workflow 
The pathway refactoring process followed the protocol we described before with slight 
modifications (7). In the partial pathway refactoring, a new helper plasmid (T7 His Helper 1) with 
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an internal N-terminal His-tag at the cloning site was used in the first tier Golden Gate reaction for 
cloning the precursor gene, while the glycosyltransferase gene was cloned into the T7 Helper 2/9 
plasmid. In the full pathway refactoring, the precursor gene, the glycosyltransferase gene, the 
disulfide bond formation protein/thioredoxin and the transporter gene were cloned into T7 Helper 
1, T7 Helper 2, T7 Helper 3, T7 Helper 4, and T7 Helper 5/9 respectively. For the listeriocytocin 
BGC, two transporter genes (Figure 3.2) were cloned into T7 Helper 5 and T7 6/9, respectively. 
 
3.4.4 Detection of the Glycosylated Precursor Peptide from Cell Pellets and Glycocin from 
Liquid Medium by MALDI-TOF MS  
For the partial refactored BGCs, cells were grown in LB medium and IPTG was added to 0.5 mM 
when the OD600 reached 0.6-0.8. Cells were grown with shaking at 18 ºC, 30 ºC and 37 ºC in 
parallel for overnight induction. Cell pellets were harvested from 1 mL of liquid culture by 
centrifugation and resuspended in 100 µL of cell lysis buffer (8 M urea, 50 mM Tris • HCl, pH 
7.5), which were then vigorously vortexed three times (30 s each time) and sonicated in ultrasonic 
bath (Branson 2800, Danbury, CT) for at least 30 min. The supernatants were then collected by 
centrifuge, desalted by ziptip and analyzed using MALDI-TOF MS. For the fully refactored BGCs, 
the supernatants of liquid culture were collected by centrifugation after overnight induction, 
desalted by ziptip and analyzed using MALDI-TOF MS. As rich media are too complex, which 
largely affect the product detection from the supernatant possibly due to ion suppression (data not 




3.4.5 Preparation of the Glycocins 
The E. coli BL21(DE3) transformant with the corresponding plasmid was streaked on an LB plate 
containing 50 µg/mL kanamycin and grew at 37 ºC overnight. A single colony was used to 
inoculate 50 mL fresh LB liquid medium and grew at 37 ºC 250 rpm for 12-14 h, which was used 
to inoculate fresh MOPS medium at 1:100 ratio for fermentation. The MOPS medium was 
prepared as described elsewhere (25). Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added 
to 0.5 mM when OD600 reached 0.6-0.8. For bacillicin CER074 and listeriocytocin, the 
temperature was then decreased to 18 ºC and maintained for 72 h. For bacillicin BAG2O, the 
temperature was decreased to 30 ºC and maintained for 144 h. For geocillicin, the temperature was 
maintained at 37 ºC for 144 h. The pH of the liquid culture was then adjusted to 2.5 by phosphonic 
acid and the supernatant was collected by centrifuging at 10000 × g for 15 min. The supernatant 
was cooled down to 4 ºC and ammonium sulfate was added slowly with stirring to reach 75% 
saturation. The precipitant was collected after overnight incubation under 4 ºC by centrifuging at 
10000 × g for 15 min and resuspended in 0.1% trifluoroacetic acid (TFA). Insoluble materials were 
removed by centrifuging at 4000 × g for 20 min and loaded to BondElute C18 solid-phase 
extraction column (Agilent Technologies, Santa Clara, CA) previously wetted with 100% 
methanol and equilibrated by 5% B (solvent A = 0.1% TFA in HPLC grade water; solvent B = 
0.1% TFA in HPLC grade acetonitrile/water). The glycocin was eluted using a step gradient with 
increasing percentage of solvent B in 50 mL volumes: 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 
45%, 50% and 100% B. Fractions containing glycocin were combined and lyophilized to dryness.  
 
Semi preparative HPLC was performed on an Agilent 1000 series HPLC system equipped with a 
Phenomenex C5 column (5 µm, 100 Å, 250 mm × 10 mm). The glycocin sample from the solid 
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phase extraction was dissolved in 0.1% TFA and applied to the column. The glycocin was eluted 
by a linear gradient from 5% B to 60 % B over 25 min with a flow rate of 4.0 mL/min. The glycocin 
containing peak was collected and lyophilized again, which was further purified by a Phenomenex 
C18 column (5 µm, 100 Å, 250 mm × 4.6 mm) by a linear gradient from 20% B to 40% B over 40 
min.  
 
Multiple mediums and induction time were used to optimize the culturing condition and MOPS 
with 3 (bacillicin CER074, listeriocytocin) or 6 days (bacillicin BAG2O, geocillicin) induction 
turned out to give the highest productivity (10-20 µg/L for bacillicin CER074, listeriocytocin and 
bacillicin BAG2O, 1 µg/L for geocillicin).  
 
3.4.6 Preparation of the Glycosylated Intermediates 
E. coli BL21(DE3) with the corresponding partial BGC was streaked on an LB plate with 
kanamycin and grew at 37 ºC overnight. A single colony was used to inoculate 50 mL fresh LB 
liquid medium and grew at 37 ºC 250 rpm for 12-14 h as the seed culture, which was used to 
inoculate 4L LB medium. The cell culture was induced when OD600 reached 0.6-0.8 by 0.5 mM 
IPTG. After 18 h induction under different temperatures (18 ºC for the bacillicin CER074 
intermediate and mynocytogin intermediate, 30 ºC for bacillicin BAG2O intermediate and 37 ºC 
for geocillicin intermediate), the cell pellet was harvested by centrifuging at 10000 × g for 15 min. 
The intermediate was then prepared by IMAC (immobilized metal affinity chromatography) as 
described previously (26). The eluted fraction was desalted by BondElute C18 solid phase 
extraction column and lyophilized to dryness, which was then purified by a Phenomenex C5 HPLC 
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column (5 µm, 100 Å, 250 mm × 10 mm) by a linear gradient from 5% B to 60 % B over 25 min 
with a flow rate of 4.0 mL/min, as described previously.  
 
3.4.7 Structure and Bioactivity Characterizations of Glycocins  
IAA assays were performed as described previously with slight modifications (9). Briefly, 
reactions containing TCEP (tris(2-carboxyethyl)phosphine) were heated for 2 min at 55 °C, cooled 
to room temperature and then iodoacetamide was added. While the chymotrypsin digestion on 
Glycocins, determination of the sugar modification, MS/MS analysis and bioassays were 




















3.5 Figures and Tables 
Figure 3.1. The workflow for rapid discovery of glycocins. A) The glycocin BGCs were predicted 
from genomic sequences that are available in NCBI (National Center for Biotechnology 
Information) by RODEO, and genes for the glycocin biosynthesis were annotated. B) The 
candidate BGCs were then refactored using a two-tier strategy and the resulting products were 











Figure 3.2. A) Sequence Similarity Network (SSN) of putative glycocin precursor peptides. 
Network was visualized with an edge cutoff E-value threshold of 10−8, with nodes colored by 
genus. Location within the network of known glycocins (including those from this study) are 
indicated. B) Precursor peptide sequences and (proposed) structures for glycocin F, sublancin, 
thurandacin, enterocin 96 and enterocin F4-9. The cysteines for disulfide bond formation are 
highlighted in yellow and glycosylated residues are highlighted in purple. The boundary of leader 
peptide and core peptide is indicated by a red arrow. C) Alignment of the glycocins discovered in 
this work as different types with the corresponding known glycocins. The cysteines for disulfide 

















Figure 3.3. A) The selected putative glycocin BGCs. B) Alignment of the putative precursor 
peptides to the precursor peptide of sublancin, a known glycocin previously discovered from 
Bacillus subtilis 168. The red arrow indicates the sites where leader peptides are predicted to be 
cleaved. Cysteines that are predicted to form disulfide bonds are highlighted in yellow. Residues 
that are predicted to be glycosylated are highlighted in purple. The mutated residues of the 
precursor peptide from Listeria monocytogenes SLCC2540 BGC to prevent proteolysis are 












Figure 3.4. The MALDI-MS results of crude extracts from E. coli with partially refactored 
glycocin BGCs. In addition to target MS peaks, other peaks (possibly endogenous peptides from 
E. coli) are also observed. Thus, the result from E. coli with empty pET28a plasmid serves as the 
negative control (MALDI-MS results of all IMAC purified glycosylated precursor peptides are 
available in Figure 3.5). A) Results from partial BGCs of bacillicin CER074, geocillicin, bacillicin 
BAG2O and empty pET28a plasmid. Peaks representing the glycosylated precursor peptides are 
highlighted in yellow. Two new peaks were observed from bacillicin CER074 and the one with 
higher mass should represent an acetonitrile adduct. B) Results from the partial BGC of 
listeriocytocin (wild type), listeriocytocin (mutated precursor) and empty pET28a. Peaks 
representing the N-terminal truncated glycosylated precursor peptide and the glycosylated 





























Figure 3.4. Continue 
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Figure 3.5. MALDI-TOF MS results of the glycosylated precursor peptides purified by IMAC. 
Bacillicin CER074 intermediate: observed 7882.235 Da, expected 7882.637 Da; geocillicin 
intermediate: observed 7992.720 Da, expected 7992.098 Da; bacillicin BAG2O intermediate: 
observed 7490.054 Da, expected 7490.408 Da; listeriocytocin intermediate: observed 9426.555 
Da, expected 9426.858 Da. An acetonitrile adduct [M+H+41]+ was also observed in the spectrum 





Figure 3.6. MALDI-TOF MS results of M9 liquid culture supernatants of E. coli expressing fully 
refactored glycocin BGCs. The MS peaks of glycocins are highlighted in yellow. The result of E. 








Figure 3.7. Structures of the identified glycocins. A) Structures of the three SunA/ThuA type 
glycocins discovered in this work. Disulfide bonds are labeled in yellow while the glycosylated 
cysteines are labeled in purple. B) The 220 nm trace of the analytical HPLC purification. Peaks 
containing target glycocins are highlighted in yellow. C) MALDI-TOF MS analysis of the purified 
glycocins (bacillicin CER074: observed 4584.861 Da, expected 4584.057 Da; geocillicin: 
observed 4223.228 Da, expected 4222.822 Da; bacillicin BAG2O: observed 3650.761 Da, 
expected 3650.159 Da; listeriocytocin: observed 4667.945 Da, expected 4667.390 Da). D) GC 
traces of the hydrolyzed and derivatized glycosylated peptides. Traces for multiple hexose 
standards (galactose, glucose and mannose) were obtained in the same procedure and shown for 
comparison. This figure was adapted from (27). Figure 3.7D made by Subhanip Biswas. 
 








Figure 3.8. Iodoacetamide (IAA) assay of purified glycocins. Results under non-reducing 








Figure 3.9. Determination of the topology of purified glycocins. All peptides were treated with 
chymotrypsin under reducing or non-reducing conditions. The anticipated proteolytic fragments 





















Figure 3.10. Structure of listeriocytocin and MS/MS analysis to determine the site(s) of 
glycosylation. Cysteine residues that form disulfide bonds are highlighted in yellow and the 
diglycosylated serine residue is highlighted in purple. The target fragment (underlined with dashed 
line) for MS/MS analysis was generated by Asp-N endoproteinase under reducing condition. 













































Figure 3.14. Coexpression of the precursor peptide of enterocin F4-9 with the corresponding 
glycosyltransferase. A) The amino acid sequence of the precursor peptide of enterocin F4-9 with 
N-terminal his-tag. B) The MALDI-MS results from the coexpression of enterocin F4-9 precursor 
peptide and the glycosyltransferase in BL21(DE3) under 37 ºC with 0.5 mM IPTG (observed: 
8665.977 Da, expected: 8665.991 Da). BL21(DE3) with empty pET28a plasmid was used as 
negative control.  
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Figure 3.15. Activity of glycocins against Bacillus cereus ATCC14579. Samples were spotted on 
LB agar in a volume of 20 μL. a-e: 20 M glycocin. f-j: 20 M glycocin and 500 mM glucose. 
Glycocins tested: (a,f) sublancin, (b,g) bacillicin CER074, (c,h) bacillicin BAG2O, (d,i) geocillicin, 
and (e,j) listeriocytocin. k: 500 mM, glucose. l: water. This figure was adapted from (27). Figure 












Figure 3.16. Antimicrobial activity assay of glycocins against Bacillus subtilis Δspβ. Figure 
































Table 3.1. List of the Tested Indicator Strains 
Phylum Strain 
Proteobacteria 
Escherichia coli JM109 
Pseudomonas aeruginosa PA01 
Firmicutes 
Methicillin-resistant Streptococcus aureus NRS384/USA300 
Vancomycin-resistant Enterococcus faecium  V583 CB807 
Listeria monocytogenes 4b F2365 
Bacillus subtilis  Δspβ               
Bacillus halodurans C-125       
Bacillus cereus ATCC14579 
 
Table 3.2. Accession numbers of the putative precursor peptides and glycosyltransferases for 
glycocin biosynthesis. A few SunS/SunA like genes have multiple neighboring SunA/SunS like 
genes.   
 





























































































4 CGGT GTGC 
5 GTGC GACT 
2/9 CCCT AGCG 
5/9 GTGC AGCG 
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Chapter 4: Discovery and Characterization of a Class IV Lanthipeptide with 
Novel Ring Topology 
4.1 Introduction 
Lanthipeptides, which is short for lanthionine-containing peptides, constitute a major family of 
ribosomally synthesized and post-translationally modified peptides (RiPPs) (1). Historically, 
lanthipeptides were named as lantibiotics due to their antimicrobial activity. Nisin, the founding 
member of the lanthipeptide class of natural products, was discovered from Lactococcus lactis in 
1928 as a substance that inhibits the growth of Lactobacillus bulgaricus (2). The subsequent 
demonstration of its broad spectrum antimicrobial activity resulted in its use in food preservation 
till today. However, since the beginning of the 21st century, the discovery rate of lanthipeptides is 
significantly increased due to technical advances in DNA sequencing and development of 
bioinformatics tools for biosynthetic gene cluster prediction and researchers began to realize that 
the activity of lanthipeptides is not restricted to antimicrobial activity (3, 4). More than a hundred 
lanthipeptides are known to date which exhibit very diverse activities including antifungal (5), 
morphogenetic (6, 7), antiviral (8), antinociceptive (9), and antiallodynic functions (10). More 
interestingly, lanthipeptide derivatives are undergoing therapeutic evaluation and have been used 
for imaging applications (11). 
 
The biosynthesis of lanthipeptides resemble most of RiPP natural products (11). The precursor 
peptide is first translated from a small open reading frame (ORF) with the leader peptide region 
and core peptide region at its N-terminal half and C-terminal half respectively. The leader peptide 
region is recognized by the corresponding lanthipeptide synthase while modifications were taken 
place at the core peptide region. The mature lanthipeptide was released by removing the leader 
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peptide by peptidase(s) encoded either in the pathway or elsewhere in the genome of the producer. 
The defining structural feature of lanthipeptides is the presence of thioether-bridged macrocycles, 
which are composed of (methyl)-lanthionine bis-amino acids. Such a ring is formed in a two-step 
process. First, either serine or threonine undergoes dehydration through beta-elimination on their 
side chains, forming dehydroalanine (Dha) or dehydrobutyrine (Dhb) respectively. Then, the 
nucleophilic attack from the thiol group from the cysteine side chain to the double bond on Dha or 
Dhb yields the thioether bond through 1,4-conjugate addition. Depending on the direction in which 
the nucleophilic attack happens, two diastereomers, DL-(methyl)lanthionine and LL-
(methyl)lanthionine can be formed (12).  
 
Based on the characteristics of lanthipeptide synthases, lanthipepides are classified into four 
subfamilies (11, 13). Class I lanthipeptides are formed by two separate synthases. LanB catalyze 
the dehydration reaction while LanC catalyzes the cyclization reaction. While Class II 
lanthipeptides are synthesized by a single LanM enzyme which harbors both a dehydratase domain 
and a cyclase domain. Both Class III and Class IV lanthipeptides are synthesized by enzymes that 
have three domains: an N-terminal lyase domain, a central kinase domain and a C-terminal cyclase 
domain (14). The main difference between Class III and Class IV lanthipeptide synthases lies in 
their cyclase domains. While the cyclase domain from Class IV synthases resembles the LanC and 
the Class II cyclase domain, the cyclase domain from Class III is more different and lacks the 
canonical coordination sites for Zn2+ ions. In Classes II – IV, the dehydration is realized through 
ATP-dependent phosphorylation of the serine/threonine hydroxyl group. In Class I, the hydroxyl 
groups are glutamylated prior to elimination which is accomplished by using glutamylated tRNA 




While more than a hundred lanthipeptides have been discovered to date, only very few of them 
belong to Class IV lanthipeptide (17). The first known Class IV lanthipeptide, venezuelin, was 
discovered from Streptomyces venezuelae (14). Although a few more Class IV lanthipeptides were 
discovered later on, all of them are clearly homologs of venezuelin (18, 19). In addition, the 
biosynthetic mechanism was much less studied for both Class III and Class IV lanthipeptides 
compared with Class I and Class II lanthipeptides. The in trans activity of the lyase and kinase 
domains from the venezuelin synthase were reconstituted in vitro and residues crucial for the 
activity of the lyase domain were identified (14, 20). The structure of venezuelin was also 
characterized by in vitro maturation of the precursor peptide combined with the tandem mass 
spectrometry (MS/MS) method (14). In the follow up studies, the structure of venezuelin was 
confirmed by producing the mature peptide from Streptomyces (18, 19). More recently, the leader 
peptide binding mechanism was elucidated in vitro. It was shown that the α-helical stretch of 
residues at the center to N-terminal region of the leader peptide was crucial for the recognition by 
the LanL, while the kinase domain was responsible for the recognition of the leader peptide (21). 
The dehydration order was also determined as N-C. Besides the biosynthetic mechanism, the 
bioactivity of Class IV lanthipeptides is also elusive. Only a moderate inhibitory activity against 
protein tyrosine phosphate 1B (PTP1B) was ever reported for streptocollin, a Class IV 
lanthipeptide discovered from Streptomyces collinus Tu 365 (18). 
 
In this work, a new group of Class IV lanthipeptide biosynthetic pathways was identified through 
bioinformatics analysis. One of the representatives from Streptomyces sp. NRRL S-1022 was 
refactored and heterologously expressed in Escherichia coli, which generates a lanthipeptide with 
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two non-overlapped rings, a new topology that distinguishs this group of Class IV lanthipeptide 
from venezuelin and its homologs. In order to further study the mechanism of ring formation, the 
LanL was expressed and purified for in vitro assays. Through analysis of the intermediates by 
MS/MS, it was found that there are multiple routes for the ring formation while the cyclase domain 
exhibits some preference on the C to N direction for cyclization. Overall, we have successfully 
identified a new Class IV lanthipeptide and studied its biosynthesis in vitro, which has expanded 
our knowledge for the Class IV lanthipeptide structures and biosynthesis. 
 
4.2 Results and Discussion 
4.2.1 Pathway Prediction and Analysis 
In order to pick a BGC with the potential to produce a Class IV lanthipeptide with unknown 
structural features, we analyzed the data in the Gene Cluster Family database, where potential 
natural product biosynthetic gene clusters (NPGCs) predicted from 830 actinobacteria genomes 
were grouped into gene cluster families (GCFs) through similarities (22). GCF128 which contains 
13 gene clusters and was classified into lanthipeptides was chosen for further analysis. Among 
these 13 gene clusters, only two genes were shown to be highly conserved: one was shown as a 
Class IV lanthipeptide synthase (LanL) based on conserved domain search in the National Center 
for Biotechnology Information (NCBI) database while the other one was supposed to be the 
precursor peptide (LanA).  Alignment of the LanAs in GCF128 has shown that two cysteine 
residues, three threonine residues, and one serine residue in the C-terminal half are conserved 
(Figure 4.1). Compare with the precursor peptide sequence of venezuelin, which has four cysteine 
residues, GCF128 clearly represents a new group of Class IV lanthipeptide BGCs which can 




4.2.2 Pathway Refactoring and Heterologous Expression in E. coli 
To further characterize the product from GCF128, one of the 13 BGCs which was predicted from 
the genome of Streptomyces sp. NRRL S-1022 was chosen for heterologous expression in 
Escherichia coli. Both the LanA and LanL were refactored by T7 promoter and terminator through 
the plug-and-play workflow we discussed in Chapter 2 (23). After expression in E. coli BL21(DE3) 
and product purification through immobilized metal affinity chromatography (IMAC), the eluate 
was analyzed on matrix-assisted laser desorption/ionization-time of flight-mass spectrometry 
(MALDI-TOF-MS) and the m/z corresponding to the precursor peptide with 2-fold dehydration 
was clearly observed (Figure 4.2).  
 
4.2.3 Product Purification and Structural Characterization 
To get more structural information, the eluate from IMAC was further purified by semiprep HPLC. 
After digested by trypsin and analyzed on MALDI-TOF-MS, most of the peaks correlate to the 
expected fragments from the linear peptide while one peak correlates to the sum of two C – 
terminal fragments with 2-fold dehydration, which serves as an evidence that the peptide is 
cyclized (Figure 4.3). To further confirm that the peptide is cyclized, an N–ethylmaleimide (NEM) 
based derivatization assay was performed. While the unmodified precursor peptide clearly 
exhibited a mass shift, there was no mass shift for the modified precursor peptide after NEM 
treatment, which clearly showed that both of the cysteine residues were involved in the cyclization 




In order to elucidate the ring topology (e.g. if the two rings are overlapped or not), the trypsin 
digested fragments of the modified peptide was analyzed by MS/MS, and the data supports a non-
overlapped ring topology (Figure 4.4). To further confirm which residue (three threonine and one 
serine residue), four LanA mutants (S44A, T49A, T51A and T52A) with each of these four 
residues mutated to alanine was coexpressed with LanL in E. coli respectively. While two fold 
dehydration was observed for both S44A and T51A, only unmodified peptides were observed for 
T49A and T51A, which supports that the modified peptide has two non-overlapped rings in which 
T49 and T51 are involved in the ring formation (Figure 4.5). 
 
Of note, the productivity of the modified precursor peptide is less than 1 ug/L, which largely limits 
further characterization of the peptide, such as the stereochemistry of its thioether crosslinks and 
bioactivity assay. While from the UV220 nm trace, we can clearly observe one large peak that was 
eluted earlier than the one containing the target mass and its molecular weight correlates to a C-
terminal truncate of the precursor peptide which was confirmed by trypsin digestion (Figure 4.6). 
Since this truncate can also be observed when the LanA was expressed alone, such digestion should 
not be related to the cyclization and performed by endogenous peptidases in E. coli. We also 
prepared three LanA mutants with the residues next to the putative cleavage site changed to alanine, 
however, the C-terminal truncates can still be observed, which supports an assumption that the 
peptide is processed by a C-terminal endogenous peptidase in E. coli (Figure 4.7). Therefore, we 
switched to use an in vitro method to get more modified peptides as well as to study the 




4.2.4 Optimization of Peptide and Protein Expression and Purification 
Originally the precursor peptide was expressed in LB and induced for expression by three hrs, 
which was a general protocol for preparing LanA. However, due to the endogenous peptidase 
digestion, the productivity was only 10 g/L. Therefore, we assume that the peptide productivity 
can be increased if we shorten the induction time while using a richer medium to maintain the final 
biomass. Therefore, the expression time was shortened to one hour and the medium was changed 
to TB, which significantly increased the productivity by ~25 fold (Figure 4.8). 
 
Similar to LanA, a construct for N-terminal his-tagged LanL for expression in E. coli was also 
built. However, through analysis by SDS-PAGE and Western Blot, there was no detectable band 
with the expected size. Therefore, the LanL was fused with an N–terminal maltose binding protein 
(MBP) in order to increase the solubility and stability, and a TEV protease digestion site was added 
between the MBP and LanL, which led to multiple detectable bands on Western Blot (Figure 4.9). 
While a faint band appeared at the expected range, most of the prominent bands had a smaller size 
than expected, which supports the fact that the LanL was truncated at its C-terminal. While we 
tried to remove the MBP-tag by treating the protein eluates by the TEV protease, we observed 
much insoluble proteins occurred after overnight digestion (Figure 4.9). Through analysis on SDS–
PAGE and MALDI–MS, we confirmed that the insoluble fraction should be the LanL, which 
suggests that the LanL alone has a poor solubility. The instability and possible poor solubility of 
LanL in E. coli may also explain why the productivity of the modified peptide is so low, as there 
might not be enough LanL to process LanA and the unmodified LanA is also prone to being 




However, in order to study the biosynthetic mechanism of LanL in vitro, the LanL should be 
prepared at a much higher purity. As the lyase and kinase domains are located at the N-terminal 
half, the C-terminal truncates might still confer partial activity and therefore disturb the reaction 
stoichiometry in vitro. Gel filtration was tried against the eluate from IMAC, which did not 
significantly increase the purity (Figure 4.10). Considering that the major contaminants are C-
terminal truncates of this protein, the N-terminal his-tag was therefore moved to the C-terminus of 
this fusion protein to avoid the coelution of truncates together with the full length protein, which 
not only yields the protein with much higher purity but also simplifies the protein purification 
process (Figure 4.10).  
 
4.2.5 In vitro Characterization of the Biosynthesis of the Class IV Lanthipeptide 
After optimization of the peptide and protein preparation method, we successfully reconstituted 
the reaction in vitro (Figure 4.11).  Compared with the unmodified precursor peptide which was 
modified by two NEM, only 2-fold dehydration was observed for the modified peptide, indicating 
both dehydration and cyclization reactions were completed in vitro. By scaling up the reaction by 
using 3 mg precursor peptide as substrate, we successfully got sufficient amount of modified 
peptide for determination of the stereochemistry of thioether crosslinks (Figure 4.12). After 
hydrolysis, derivatization and GC/MS analysis, it appears that both thioether crosslinks in our 
lanthipeptide are in the form of DL-methyllanthionine.  
 
To further study the biosynthetic mechanism, the in vitro reaction time was shortened to 10 min in 
order to get the biosynthetic intermediates. Fortunately, a series of intermediates were observed 
on MALDI-TOF-MS. After digestion by trypsin, the corresponding fragments were analyzed on 
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both MALDI-TOF-MS as well as MS/MS in order to get more structural information (Figure 4.11 
and Figure 4.14). The structures of all intermediates detected reveal that there might be multiple 
routes for the biosynthesis of this lanthipeptide. Although there are some evidence showing that 
the dehydration of venezuelin happens at an N-C direction, both dehydration and cyclization of 
this lanthipeptide can happen from both N-C and C-N direction. 
 
To further validate this hypothesis as well as to explore if there is any biosynthetic route that the 
lanthipeptide synthase prefers, two mutants of the precursor peptides were prepared (T49A and 
T52A) for in vitro reaction (Figure 4.13 and Figure 4.14). After 1h reaction, T49A was completely 
converted to the corresponding product with the C–terminal ring formed. However, T52A was 
partially converted into the product with the N–terminal ring formed while the intermediate with 
1-fold dehydration was also observed, which means that the cyclization may prefer the C–N 
direction. Of note, another intermediate with 2-fold dehydration was also observed, which implies 
that the lyase/kinase domain(s) might not be very specific.  
 
4.3 Conclusion 
In this chapter, we successfully applied our pathway refactoring workflow to the discovery of a 
novel Class IV lanthipeptide from Streptomyces sp. NRRL S-1022. While very limited members 
of Class IV lanthipeptides have been discovered to date and all of them exhibit similar structural 
features (e.g. venezuelin and its homologs), the lanthipeptide discussed in this chapter exhibits a 
completely novel ring topology.  To further study its biosynthetic mechanism, the expression and 
preparation process for both the precursor peptide and the synthase was optimized. The 
biosynthetic reaction for this lanthipeptide was successfully reconstituted in vitro and the analysis 
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of its intermediates reveal its biosynthetic route. Multiple biosynthetic routes should co-exist 
during the biosynthesis. While the dehydration reactions may not have strong preference from 
either N–C or C–N direction compared with the biosynthesis of venezuelin which confers an N–C 
dehydration order, the cyclization reactions should prefer a C–N direction, although it can also 
happen in both ways. Overall, in this chapter we not only discovered a novel Class IV lanthipeptide 
with unprecedented structural features, but also generate more knowledge about the biosynthesis 
of Class IV lanthipeptides. 
 
4.4 Materials and Methods 
4.4.1 Bacterial Strains and Materials 
E. coli DH5a cells were used for cloning and mutagenesis. E. coli BL21(DE3) cells were used for 
expression. The Streptomyces sp. NRRL S-1022 strain used in this study was obtained from the 
United States Department of Agriculture Agricultural Research Service (USDA ARS) collection 
(Peoria, IL). All plasmids were validated via sequencing (carried out by ACGT, Inc.). All the 
enzymes for cloning were obtained from New England Biolabs (Ipswich, MA), oligonucleotide 
primers from the Integrated DNA Technologies (Coralville, IA), and trypsin from Worthington 
Biochemical Corp (Lakewood, NJ). Lysozyme, benzonase (25–29 U/μL), Millipore C18 Ziptips 
were purchased from Thermo Fisher Scientific (Waltham, MA). 
 
4.4.2 Coexpression of the Precursor Peptide and Synthase and Purification of the Modified 
Peptide 
The pET28a plasmid containing the precursor peptide gene and the synthase was constructed by 
the plug-and-play workflow as described previously (23). Two 4 L baffled flasks, carrying 2 L of 
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LB each, were inoculated 1:100 with an LB overnight culture and grown at 37 °C until reaching 
an OD600 of 0.6–0.8. Cultures were induced by addition of 1 mL of IPTG stock solution (1 M) 
per flask and continued shaking under 18 °C for another 18 – 20 h. Cells were harvested by 
centrifugation and resuspended in LanA start buffer (20 mM NaH2PO4, pH 7.5 at 25 °C, 500 mM 
NaCl, 0.5 mM imidazole, 20% glycerol) and lysed by sonication with the following settings: 35% 
amplitude, 15 min total sonication time; 4.0 s on / 9.9 s off-pulse. The cell lysate was then 
centrifuged at 18,000 rpm for 30 min and the supernatant was collected as the soluble fraction. 
While the precipitant was dissolved into the guanidine lysis buffer (6 M guanidine hydrochloride, 
20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, pH 7.5), sonicated and centrifuged again by 
using the same setup, and the supernatant was collected as the insoluble fraction.  
 
Either the soluble fraction or insoluble fraction was then purified by IMAC. The 5 mL HisTrap 
column (GE Healthcare) was equilibrated by guanidine lysis buffer and the sample was then loaded 
by a peristaltic pump. The HisTrap column was then washed by guanidine wash buffer (4 M 
guanidine hydrochloride, 20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5) and eluted 
with 15 mL of guanidine elution buffer (4 M guanidine hydrochloride, 20 mM Tris, 100 mM NaCl, 
1 M imidazole, pH 7.5).  The elution fraction was desalted by BondElute C18 solid phase 
extraction column (Agilent). After lyophilization, the peptide powder was dissolved into 5 mL 
water with 0.1% (v/v) trifluoroacetic acid (TFA) and cleaned by 0.22 um filter for semiprep HPLC 
purification with 0.1% (v/v) TFA (A) and MeCN–0.1% (v/v) TFA (B) at 3 mL/min and the 
following gradient: linear gradient of 5%–80% B over 30 min, followed by a linear increase of 
80–100% B over 1 min and holding 100% B for another 5 min. The elution fractions containing 




4.4.3 Expression and Purification of the Precursor Peptide 
The pET28a plasmid containing the precursor peptide gene under control of T7 promoter was 
expressed in E. coli BL21(DE3). Two 4 L baffled flasks, carrying 2 L of TB each, were inoculated 
1:100 with an LB overnight culture and grown at 37 °C until reaching an OD600 of 0.6–0.8. 
Cultures were induced by addition of 200 μL of IPTG stock solution (1 M) per flask and harvested 
after expression for 1 h at 37 °C. Cells were resuspended in guanidine lysis buffer (6 M guanidine 
hydrochloride, 20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, pH 7.5) to a final volume of 
35–40 mL and lysed at room temperature by sonication with the following instrument settings: 60% 
amplitude, 5 min total sonication time; 5 s on / 5 s off-pulse. 
 
After centrifugation for 30 min at 18,000 rpm and 4 °C, the supernatant was sonicated again for 1 
min at the same settings to further shear the DNA to allow easy filtration through a syringe filter 
(0.45 μM). After filtering, the lysates were applied to IMAC purification as described above. In 
this way, the precursor peptide could be obtained with yields of ∼0.25 mg/L expression culture. 
The elution fractions containing the target peptide were lyophilized, redissolved in 0.1% (v/v) TFA 
with the concentration determined by NanoDrop (ThermoFisher, Waltham, MA) and stored under 
-80 °C.  
 
4.4.4 Protein Expression and Purification 
The MBP tagged LanL was expressed for 18 – 20 h at 18 °C in 4 L baffled flasks containing 2 L 
of TB medium using the conditions described above. Cell pellets from 4 L of cultures were 
resuspended in lysis buffer, yielding a final volume of 35–40 mL. Cells were incubated on ice with 
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lysozyme (50 mg) and benzonase (5 μL) for 1 h and subsequently lysed by sonication on ice with 
the following settings: 60% amplitude, 5 min total sonication time; alternating between 2 s on / 5 
s off-pulse. 
 
Lysates were centrifuged twice for 30 min at 4 °C and 18,000 rpm (supernatants were transferred 
into fresh centrifuge tubes in between centrifugation steps) and filtered through a syringe filter 
(0.45 μm). IMAC purification was performed using a 5 mL HisTrap column (GE Healthcare) using 
fast protein liquid chromatography (FPLC) with buffer A (300 mM NaCl, 50 mM NaH2PO4, 20 
mM imidazole, pH 8.0) and buffer B (300 mM NaCl, 50 mM NaH2PO4, 250 mM imidazole, pH 
8.0) at 5 mL/min. After loading, the column was washed by approximately 100 mL buffer A till 
the UV 280 nm absorption fell below 20 mAU and then eluted with the following gradient: linear 
gradient of 0 – 100% B over 9 min followed by 100 % B for another 6 min. Elution fractions were 
cleaned by 0.22 μm filter and concentrated with Amicon centrifugal filter units with 100 kDa MW 
cut-off to around 500 μL. The original buffer was also exchanged to the storage buffer (300 mM 
NaCl, 50 mM HEPES, 10% glycerol at pH7.5) and the concentration was determined by NanoDrop. 
The protein was then snap – freezed and stored at -80 °C. 
 
4.4.5 In vitro Enzymatic Assays 
A typical enzyme assay contained 20 μL of 2× buffer (300 mM NaCl, 50 mM HEPES, pH 7.5), 2 
μL of tris(2-carboxyethyl)phosphine (TCEP) stock solution (20 mM in H2O), 2 μL of MgCl2 stock 
solution (200 mM in H2O), 2 μL of ATP stock solution (50 mM in H2O), 2 μL of the precursor 
peptide stock solution (10 mg/mL in 0.1% (v/v) TFA, which yields a final concentration of 65 μM 
in the assay) and corresponding amounts of protein stock solution and H2O to obtain a final volume 
108 
 
of 40 μL at a concentration of 2.5 μM for the protein. The reaction was run overnight at room 
temperature and then 20 μL of the sample was purified and eluted into 10 μL of 70% (v/v) 
MeCN/0.1% (v/v) TFA using C18 Ziptips following the manufacturer’s protocol. 1 μL samples 
were prepared for MALDI-TOF-MS by mixing with 1 μL of 15 mg/mL α-cyano-4-
hydroxycinnamic acid (CHCA) in 70% (v/v) MeCN/0.1% (v/v) TFA. 
 
4.4.6 Determination of the Reaction Order 
To determine the order of the dehydration and cyclization, 60 μL assay reactions were set up as 
described above and the reaction was either stopped after 10 min or 60 min. 20 ul aliquots of the 
reaction were quenched in a thermocycler by holding the temperature at 95 °C for 5 min. The 
reaction mixture was then lyophilized, redissolved by 20 μl guanidine buffer with 1 μL of TCEP 
stock solution (100 mM in H2O) and incubated for 15 min at 50 °C. Then, 1 μL of NEM stock 
solution (400 mM in EtOH) was added, and after mixing, the reaction was run for 1 h at room 
temperature. The peptide was purified and eluted into 20 μL of 70% (v/v) MeCN/0.1% (v/v) TFA 
using C18 Ziptips following the manufacturer’s protocol and prepared for MALDI-TOF-MS by 
mixing 1 μL of sample with 1 μL of 15 mg/mL CHCA in 70% (v/v) MeCN/0.1% (v/v) TFA to 
confirm the existence of intermediates. The sample prepared by C18 Ziptip was lyophilized again 
and redissolved into 50 mM Tris HCl, 1 mM CaCl2, pH 7.6 with 0.15 mg/mL trypsin. After 
incubation for 3 h at room temperature, the reaction was purified and eluted into 20 μL of 70% 
(v/v) MeCN/0.1% (v/v) TFA using C18 Ziptips again and analyzed by MALDI-TOF-MS. For 
MS/MS analysis on Q Exactive™ Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (Thermo 



























Figure 4.2. Modified precursor peptide with 2-fold dehydration (m/z observed: 7714.4) and 






































































Figure 4.6. A) UV220nm trace for soluble and insoluble fractions. a: C-terminal truncated peptide; 






Figure 4.7. MALDI-TOF-MS results for desalted IMAC purified E. coli cell lysates with LanA 






Figure 4.8. UV220nm trace for purification of LanA on semiprep HPLC. Peaks containing the 



















Figure 4.9. A) The organization and the corresponding size of the MBP-LanL fusion protein. B) 
SDS-PAGE of the fractions from IMAC purification. C) Western Blot of the fractions from IMAC 
purification. D) SDS-PAGE of the IAMC eluates digested by TEV protease. E) MALDI-TOF-MS 






























Figure 4.10. A) UV 280nm trace for purification of the MBP-LanL IMAC eluates on HiLoad 
16/600 Superdex 200 pg gel filtration column. B) SDS-PAGE of fractions from gel filtration 


































Figure 4.11. A) In vitro enzymatic assay stopped at either 10 min or 60 min. B) The trypsin 
digested results of 10 min reaction on MALDI-TOF-MS. C) The trypsin digested results of 60 min 





























































Figure 4.12. Extracted ion chromatogram of the stereochemistry determination of thioether 












Figure 4.13. In vitro enzymatic reaction using T49A and T52A as substrates. Peptide fragments 
























Figure 4.14. MS/MS analysis of all peptide fragments obtained from in vitro enzymatic reaction 
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Chapter 5: Characterization of the Heat Stable Antifungal Factor (HSAF) Gene 
Cluster Reveals a Parallel Biosynthetic Mechanism 
5.1 Introduction 
Polyketides (PK) and nonribosomal peptides (NRP), as well as their hybrids, constitute one of the 
largest family of natural products with interesting biological activities (1). Thousands of PKs and 
NRPs are known to date and many of them are used as drugs for years or currently under clinical 
trials. The widely used PK antibiotics include erythromycin and tetracycline while the NRP 
antibiotics include penicillin and cephalosporin families (2-5). There are also many medicinally 
relevant hybrids such as the immunosuppressant drugs FK506 and rapamycin (6, 7). Although 
both PKs and NRPs are structurally and functionally diverse, they all arise from combinatorial 
utilization and elongation of simple building blocks. Malonyl-CoA and methylmalonyl-CoA are 
two major monomers used for PK elongation and the canonical and noncanonical amino acids are 
used for NRP biosynthesis. While the elongation is catalyzed by the polyketide synthase (PKS), 
the nonribosomal peptide synthase (NRPS) or the PKS-NRPS hybrid, tailing enzymes that are 
usually observed in the pathway can introduce more structural features to the final products, and 
some of these features are critical to the bioactivity. Based on the understanding of their 
biosynthesis, many efforts have been spent on developing artificial PKs, NRPs, and the hybrids by 
combinatorial approaches (8). Therefore, characterization of the biosynthetic mechanisms of 
unknown pathways for PKs, NRPs and their hybrids is of great interest.  
 
Polycyclic tetramate macrolactams are a group of PK-NRP hybrids which contain one tetramic 
acid and a polycyclic system (usually 2-3 rings) which exhibit diverse biological activities such as 
antifungal, antibacterial and antioxidant properties (9-12). The potential PTM compounds were 
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first reported in 1985, when two isomers named catacandins A and B were isolated from 
Lysobacter gummosus ATCC 39742. However, the structure of PTM remain to be elusive until the 
1990s, when two PTMs, named discodermide and clindramide, were isolated from sponges with 
their structures fully elucidated (13, 14). Recently, more PTMs were discovered from various 
origins, such as maltophilin from Stenotrophomonas maltophilia (11), heat-stable antifungal factor 
(HSAF) from Lysobacter enzymogenes (12, 15) as well as ikarugamycin (16) , dihydromaltophilin 
(10), and frontalamides from Streptomyces sp (9).  
 
The heat-stable antifungal factor (HSAF) was one of the PTMs discovered from L. enzymogenes 
strain C3, which is a biological control agent originally isolated from grass foliage (17). This strain 
was demonstrated to reduce diseases caused by multiple fungal pathogens and the search for 
antifungal factors then lead to the isolation of HSAF. HSAF was demonstrated to be active against 
a broad range of fungal pathogens and its mode of action was studied using Aspergillus nidulans 
as a test organism (18). The polarized growth of fungus was disrupted by HSAF and further 
analysis of genetic mutants of Aspergillus nidulans suggested that HSAF targets the biosynthesis 
of sphingolipids. Another study also revealed that HSAF can induce the accumulation of 
intermediates in sphingolipid biosynthesis, which can lead to thickening of the cell wall and thus 
increased chitin deposition and irreversibly blocking elongation of the hyphal tips (19). 
Interestingly, only a distinct group of sphingolipids which is observed in filamentous fungi but 
absent from mammals and plants appears to be the target of HSAF, making HSAF a potential 




Although HSAF as well as other PTMs exhibit interesting bioactivities, their biosynthetic 
mechanisms remain to be elusive. The proposed mechanism for PTM biosynthesis starts from the 
backbone formation catalyzed by a PKS-NRPS hybrid, which incorporates 12 malonyl-CoA 
monomers and one tetramic acid. Later, the carbon chain was modified by a series of 
oxidoreductases which introduce the polycyclic system as well as other groups such as hydroxyl 
and epoxide groups. In 2013, Zhao and coworkers successfully activated a silent PTM gene cluster 
from Streptomyces griseus by pathway refactoring. Through constructing the pathway with 
different gene knockouts, they proposed a biosynthetic route with multiple branches (20). While 
the PKS-NRPS hybrid together with two oxidoreductases in the pathway catalyze the formation 
of a key intermediate compound c, the other three enzymes in this pathway, including one 
oxidoreductase, one cytochrome P450 and one hydroxylase, further turn this key intermediate into 
three different products. The parallel biosynthetic mechanism is intriguing as in most of the cases 
one gene cluster generates only one final product. Therefore, it would be interesting to further 
investigate if such a parallel biosynthetic mechanism is widely distributed among other PTM 
pathways. 
 
In this work, the biosynthetic mechanism of HSAF was investigated. Four constructs that are 
supposed to make different intermediates in the HSAF biosynthesis were built by DNA assembler 
(21). These constructs were then transformed into Streptomyces lividans 66 for expression and 
three intermediates were isolated with their structure characterized by tandem mass spectrometry 
(MS/MS) or nucleic magnetic resonance (NMR). The structural information clearly supports the 
assumption that the HSAF pathway also has a parallel biosynthetic mechanism. In addition, the 
distribution of PTM pathways among different microorganisms were also analyzed. Two short 
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PTM pathway representatives were also refactored for heterologous expression in different 
Streptomyces strains, which led to poor growth of the host and implied the generation of 
compounds that has antimicrobial activity. 
 
5.2 Results and Discussion 
5.2.1 Refactoring the HSAF Pathway to Produce dOH-HSAF in Streptomyces lividans 
The HSAF pathway consists of six genes, including one hydroxylase gene, one PKS-NRPS hybrid 
gene and four oxidoreductase genes. While the activity of the hydroxylase gene has already been 
characterized in vitro, only the other five genes were refactored (22). In order to confirm if all of 
the five genes can be successfully expressed in Streptomyces lividans, they were refactored by 
DNA assembler as described previously which generated Construct D (Figure 5.1). Construct D 
was then transformed into S. lividans 66 through conjugation and expressed for seven days on 
ISP2 agar plate under 30 °C. The product was then extracted by ethyl acetate and concentrated for 
high performance liquid chromatography-mass spectrometry (HPLC-MS) analysis. A peak under 
UV 280nm was observed around 28 min with the corresponding m/z of 497.3014, which is 
identical to the molecular weight of the reported deOH-HSAF (calculated m/z: 497.2971, an 
intermediate in HSAF biosynthesis obtained through knockout the hydroxylase in the native 
producer (Figure 5.2).   
 
5.2.2 Design of Partially Refactored HSAF Pathways 
As all of the five genes under investigation were shown to be active in the heterologous host, we 
proceeded to design constructs with other gene combinations to further investigate the biosynthetic 
mechanism. Sequence analysis of the four oxidoreductases (OX1-OX4) in the PTM pathway from 
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S. griseus showed that both OX1 and OX2 are homologous to SGR813, OX3 is homologous to 
SGR812 and OX4 is homologous to SGR811, while the SGR810 homolog is not observed in the 
HSAF pathway. Based on the proposed biosynthetic mechanism for the PTM pathway in S. griseus, 
another three constructs were designed as follows: Construct A contains the PKS-NRPS hybrid 
with OX2 and OX3 which is supposed to generate the key intermediate; OX1 and OX4 were added 
to Construct A respectively which generate Construct B and Construct C (Figure 5.1). If the HSAF 
pathway follows the parallel mechanism as assumed, Construct B and Construct C should produce 
different compounds. 
 
5.2.3 Characterization of the Compounds Produced by the Partial HSAF Pathways 
Construct A/B/C were built by DNA assembler and transformed into S. lividans 66 for expression 
as described previously. The products were also extracted and analyzed by the same approach used 
for dOH-HSAF.  Initial HPLC-MS analysis indicated that the 3-gene cluster of the HSAF pathway 
(Construct A) produced an intermediate with a corresponding m/z of 477.2815, which is nearly 
identical to a proposed intermediate with a single ring. The chemical structure was subsequently 
confirmed by 1D and 2D NMR (COSY, HSQC and HMBC) (Figure 5.3 and Figure 5.4). The 4-
gene HSAF cluster (Construct B) produced an intermediate with the same retention time with the 
deOH-HSAF produced by the five-gene HSAF cluster (Construct D). The corresponding m/z of 
497.3014 further confirmed that the product from this four-gene cluster is deOH-HSAF. Another 
4-gene HSAF cluster (HSAF-C) revealed the production of an intermediate with a relatively longer 
retention time compared to deOH-HSAF and a corresponding m/z of 495.2853 (Figure 5.2). 
Compared with the MS/MS data of previously characterized compounds, this intermediate was 




5.2.4 Analysis of the Distribution of the PTM Pathways and Characterization of the PTM 
Pathways from Saccharophagus degradans and Salinospora arenicola 
In order to further investigate if the parallel biosynthetic mechanism exists in PTM biosynthetic 
gene clusters, over 800 sequenced actinobacterial genomes were analyzed for the existence of 
PTM gene cluster homologs (Figure 5.5). Most of these gene clusters reveal similar combination 
of biosynthetic genes as the HSAF pathway and the one previously discovered from S. griseus. 
Besides the five-gene clusters, three-gene clusters and six-gene clusters were also observed in 
some strains, which may produce PTMs with different structural features from the known ones. 
 
As there is no report for any PTMs produced from these short gene clusters, two of them were 
picked for characterization by using the same approach for the HSAF cluster (Figure 5.5). The 
cluster from Saccharophagus degradans contains only three genes with only one oxidoreductase 
which is the homolog to SGR812. The cluster from Salinospora arenicola contains four genes 
which resemble the gene cluster for ikarugamycin biosynthesis. However, after refactoring and 
transformation into multiple Streptomyces strains for expression (S. lividans 66, S. albus J1074, S. 
coelicolor M1146, and S. coelicolor M1152), all hosts showed a very poor cell growth rate and 
thus no product was detected. However, such a phenomenon implied that the potential products 
from these two pathways might have antimicrobial activity. 
 
5.2.5 Proposed Mechanism of PTM Biosynthesis 
The results from the four HSAF constructs suggest a parallel biosynthetic mechanism of the HSAF 
pathway. The OX2 and OX3 are critical for the synthesis of the key intermediate 1. While OX4 
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can further convert this intermediate into a three-ring product deOH-HSAF 2, OX1 can convert it 
into a two-ring product compound 3 (Figure 5.6).  The formation of the bicyclic scaffold or the 
tricyclic scaffold is determined by the differential expression of two critical oxidoreductases 
involved in these PTM biosynthetic gene clusters. Bioinformatics analysis of over 800 sequenced 
actinobacteria genomes revealed the wide distribution of the PTM biosynthetic pathways, which 
indicates the general presence of this parallel biosynthesis mechanism in actinobacteria. This 
mechanism might be evolutionarily advantageous when generating a new natural product 
biosynthetic pathway because several genes can be shared and fewer mutational steps are required 
to meet a new selective pressure. In fact, there are PTM biosynthetic pathways only consisting of 
three genes, which may be the minimal set to produce a desired natural product against 
environmental pressure. For example, the PTM gene cluster from Saccharophagus degradans only 
contains homologs of SGR812, SGR815 and SGR814, which supports the proposed role of 
SGR812 in the first ring formation and compound 1 as the key intermediate. As in Salinospora 
arenicola and the ikarugamycin producing strain, the SGR811 homologs are found downstream 
of the SGR812 homolog, while no SGR813 homologs are found. Based on the structure of 
ikarugamycin, the function of SGR811 homologs can be proposed as forming the inner two-ring 
structure. 
 
In addition, there are PTM pathways with six genes, which may be able to produce two sets of 
compounds to deal with different selection pressure. Taken the PTM pathway from S. griseus as 
an example, SGR811 and SGR813 are the two key enzymes tuning the expression of this pathway 
into two branches. These two enzymes are annotated as oxidoreductases and can be found in most 
of the known PTM gene clusters. Based on phylogenetic analysis, these two enzymes are distinct 
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and this is probably why they could catalyze different reactions even though they belong to the 
same family of oxidoreductases. If these 6-gene containing PTM pathways are evolved from the 
3-gene pathways, the evolutionary changes presented here would be quantitative, not qualitative. 
The quantitative changes are important in evolutionary diversification. In the PTM evolution, 
rather than incorporating a promiscuous enzyme for new compounds, one additional gene is 
inserted into an existing pathway to generate diversity. To our knowledge, this is by far the first 
example of multiple natural products generated from the same gene cluster by the tuning of two 
key genes. More importantly, this phenomenon is prevailing in nature because the PTM 
biosynthetic machinery is well preserved. 
 
5.3 Conclusion 
In this work, the biosynthesis of HSAF was characterized by pathway refactoring and heterologous 
expression in S. lividans. Structural characterization of the intermediates produced by different 
partial HSAF pathways reveal a parallel biosynthetic route that is similar to that in the PTM 
pathway discovered from S. griseus. Bioinformatic analysis indicates that this mechanism may be 
a general mechanism in PTM biosynthesis. 
 
5.4 Materials and Methods 
5.4.1 Strains and Materials  
Saccharomyces cerevisiae HZ848 (MATα, ade2-1, Δura3, his3-11, 15, trp1-1, leu2-3, 112 and 
can1-100) was used as the host for DNA assembly. S. lividans 66 was obtained from the 
Agricultural Research Service Culture Collection (Peoria, IL). Lysobacter enzymogenes strain C3 
was a gift from Dr. Liangcheng Du (University of Nebraska-Lincoln, NE). Plasmids pAE4, E. coli 
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strain BW25141 [lacIq , rrnBT14, ΔlacZWJ16, ΔphoBR580, hsdR514, ΔaraBADAH33, 
ΔrhaBADLD78, galU95, endABT333, uidA(ΔMluI)∷ pir+ recA1, derived from E. coli K-12 
strain BD792] and E. coli strain WM6026 [lacIq, rrnB3, ΔlacZ4787, hsdR514, ΔaraBAD567, 
Δ rhaBAD568, rph-1, attl::pAE12 (Δ oriR6K-cat::Frt5), Δ endA::Frt, uidA(ΔMluI)::pir, 
attHK::pJK1006 Δ (oriR6K-cat::Frt5; trfA::Frt)] were provided by Dr. William Metcalf 
(University of Illinois, Urbana, IL). The plasmid pRS416 was purchased from New England 
Biolabs (Ipswich, MA).  Nalidixic acid and Isopropyl ß-D-1-thiogalactopyranoside (IPTG) were 
obtained from Sigma-Aldrich (St. Louis, MO). ISP2, agar, beef extract, yeast extract, malt extract, 
and other reagents required for cell culture were obtained from Difco (Franklin Lakes, NJ). All 
restriction endonucleases and Q5 DNA polymerase were purchased from New England Biolabs. 
The QIAprep Spin Plasmid Mini-prep Kit, QIAquick PCR Purification Kit, QIAquick Gel 
Extraction Kit were purchased from Qiagen (Valencia, CA). Wizard Genomic DNA isolation kit 
was from Promega (Madison, WI). Zymoprep II Yeast Plasmid Miniprep kit was purchased from 
Zymo (Zymo Research, CA). All primers were synthesized by Integrated DNA Technologies 
(Coralville, IA). Yeast YPAD medium containing 1% yeast extract, 2% peptone and 2% dextrose 
supplemented with 0.01% adenine hemisulphate was used to grow S. cerevisiae HZ848. Synthetic 
complete drop-out medium lacking uracil (SC-Ura) was used to select transformants containing 
the assembled biochemical gene clusters of interest. MYG liquid medium containing 4% yeast 
extract, 10% malt extract, 4% glucose and YMS solid agar medium containing 4% yeast extract, 




5.4.2 Gene Cluster Reconstruction and Yeast Transformation 
Gene cluster fragments were amplified from the genomic DNA of L. enzymogenes strain C3, 
respectively. The S. cerevisiae helper fragment was amplified from the plasmid pRS416, whereas 
the E. coli helper fragment and the S. lividans helper fragment were amplified from pAE4 (23). 
The PCR products were individually gel-purified from 1% agarose. Promoters from other hosts 
were obtained through previous studies (24, 25). Genes with corresponding promoters were ligated 
together by overlap extension PCR. To ensure high efficiency of yeast homologous recombination, 
the “promoter upstream-gene-promoter downstream” cassette was built to generate a ~200 bp 
overlap region with adjacent fragments. The cassettes were mixed and concentrated, then 
electroporated into S. cerevisiae following the DNA assembler protocol (21). 
 
5.4.3 Heterologous Expression in S. lividans 
The verified clones were transformed to E. coli WM6026 and selected on LB agar plates 
supplemented with 19 µg/mL 2,6-diaminopimelic acid and 50 µg/mL apramycin. These 
transformants were then used as the donors for conjugative transfer of the assembled plasmids to 
S. lividans 66 following the protocol described elsewhere (26). S. lividans exconjugants were 
picked and re-streaked on ISP2 plates supplemented with 50 µg/mL apramycin and grown for 2 
days. Then a single colony was inoculated into 15 mL of MYG liquid medium supplemented with 
50 µg/mL apramycin in a 125 mL shake-flask (3 mm glass beads added to improve liquid mixing 
and aeration). Aliquots of this seed culture with a volume of 250 μL were spread for confluence 
over Petri plates containing approximately 25-30 mL of YMS solid agar medium (4 g/L yeast 
extract, 10 g/L malt extract, 4 g/L soluble starch, and 20 g/L Bacto agar) and the plates were 




5.4.4 HPLC-MS Analysis 
To isolate potential compounds, agar and the adherent cells were stored at -80 °C for at least 24 h, 
after which the frozen cultures were thawed completely and the released liquids were collected. 
The liquids were extracted by ethyl acetate with a ratio of 1:1 twice, concentrated 1000-fold, and 
subjected to HPLC analysis. HPLC was performed on the Agilent 1100 series LC/MSD XCT plus 
ion trap mass spectrometer with a Phenomenex Luna C18 reverse-phase column (3.0 x 150 mm, 
3.5 μm). HPLC parameters were as follows: solvent A, 0.1% formic acid in water; solvent B, 0.1% 
formic acid in acetonitrile; gradient, 10% B for 5 min, to 100% B in 25 min, maintain at 100% B 
for 10 min, return to 10% B in 1 min and finally maintain at 10% B for 9 min; flow rate 0.3 mL/min; 
detection by UV spectroscopy at 260 nm and 400 nm. The MS system was operated using a drying 
temperature of 350 C, a nebulizer pressure of 35 psi, a drying gas flow of 8.5 L/min, and a capillary 
voltage of 4500 V. 
 
5.4.5 Structure Elucidation of Compound 1 
 Compound 1 was isolated by reverse-phase HPLC using a Phenomenex Luna 10u C18 column 
(10 mm × 250 mm), on the Agilent 1100 series LC/MSD XCT with an isocratic solvent of 60% 
acetonitrile in water with 0.1% formic acid (with a flow rate of 3 mL/min and a wavelength of 260 
nm). The high resolution MS was performed on a Waters Q-Tof Ultima system (Walters, Milford, 
MA). All NMR experiments were carried out on a Varian UNITY INOVA 600 MHz spectrometer, 
except the 13C spectra, which were recorded on a Bruker Avance III 500i with a 5 mm 13C(1H) 
cryogenic probe at the National Magnetic Resonance Facility at the University of Wisconsin at 















Figure 5.2. UV 280nm traces for crude extracts from S. lividans 66 with Construct A/B/C/D on 
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Figure 5.5. Representatives of PTM biosynthetic gene clusters. 1. SGR815 homologs; 3: SGR813 
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Chapter 6: Development of CRISPR-based Genetic Tools for Natural Product 
Discovery and Overproduction in Streptomyces Species 
6.1 Introduction 
Streptomycetes are filamentous, Gram-positive bacteria with high GC content genomes that are 
predominantly found in soil and water environments. The most notable property of this genus is 
their ability to produce pharmaceutically relevant secondary metabolites including antimicrobial, 
antifungal, antiviral, antihypertensive, immune suppressant and antitumor activities (1). In 2002, 
when the genome of a streptomyces species, Streptomyces coelicolor A3(2), was fully sequenced 
for the first time, the authors identified more than 20 biosynthetic gene clusters (BGCs) encoding 
secondary metabolites (2). Although some of them were already known, others had not yet been 
identified. Since then, an increasing number of streptomyces species were sequenced and each 
encodes dozens of BGCs. Besides being a prolific resource for discovery of new compounds, 
streptomycetes are also ideal chassis for overproducing natural products. Adequate substrates 
along with multiple post-translational modification systems are available in streptomycetes, which 
are necessary for natural product biosynthesis. To date, metabolic engineering approaches have 
been successfully used for optimizing the productivity of some pharmaceutically important natural 
products in a few Streptomyces species (3). However, the existing genetic tools for engineering 
streptomycetes are generally time-consuming and inefficient.  
 
Clustered regularly interspaced short palindromic repeats (CRIPSR)-Cas9 system has been 
developed as a powerful genetic engineering tool for both eukaryotes and prokaryotes (4, 5). The 
most widely used Type II CRISPR-Cas9 system from Streptococcus pyogenes consists of the Cas9 
nuclease and a chimeric single guide RNA (sgRNA). The 20 nt protospacer sequence in sgRNA 
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can help Cas9 specifically recognize the designated DNA sequence and perform double strand 
cleavage. Because of its excellent specificity in target recognition, the CRISPR-Cas9 system was 
further developed into CRISPR interference (CRISPRi) system (6). The CRISPRi system consists 
of a nuclease deficient Cas9 (dCas9) which can recognize the target sequence but cannot perform 
cleavage. Through targeting either the transcription initiation region or the coding region, 
CRISPRi can specifically and reversibly repress the expression of its target gene. Furthermore, if 
the dCas9 is fused with transcriptional activator and guided to the suitable site, it is able to recruit 
RNA polymerase (RNAP) and therefore improve the expression level of target gene, which is 
referred as CRISPRa (7-10). The application of CRISPR-Cas9 in several streptomycetes and 
CRISPRi in S. coelicolor were first demonstrated in 2015 by several research groups (11-14). 
However, there is still no published data showing the activity of CRISPRa in streptomycetes. In 
this chapter, I demonstrated the activity of CRISPRi system in both Streptomyces lividans 66 and 
Streptomyces albus J1074, which are two most widely used model Streptomyces strains as S. 
coelicolor. By fusing the dCas9 with the RNAP-ω factor, CRISPRa was also proved to be active 
in S. lividans 66 through activation of the undecylprodigiosin (RED) gene cluster. To achieve 
titratable repression, an inducible promoter was used for sgRNA expression. However, further 
optimization is needed to broaden the tunable range for expression. 
 
6.2 Results and Discussion  
6.2.1 Characterization of a CRISPRi System in S. lividans 66 and S. albus J1074 
In order to characterize the activity of dCas9 in S. lividans 66 and S. albus J1074, XylE, a widely 
used sterptomycetes reporter that can convert the colorless substrate catechol to an intensely 
yellow hydroxymuconic semialdehyde, was chosen as the target gene. The xylE expression 
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cassette along with the sgRNA under the control of gadph promoter and oop terminator were 
cloned into the pSET-dCas9 plasmid obtained from AddGene (15). Two sgRNAs targeting both 
the template (xylE-T) and nontemplate strand (xylE-NT) of the coding region of xylE were tested. 
In both strains, only the sgRNA targeting the nontemplate strand exhibited significant repression 
(Figure 6.1). Such an observation is consistent with the results published by Tong and coworkers, 
in which the production of actinorhodin in S. coelicolor was significantly repressed only when the 
sgRNAs targeted the nontemplate strand in the coding region of its key biosynthetic gene 
actIORF1 (13). Since the CRISPRi system showed higher level of repression in S. lividans 66, the 
following experiments were performed in S. lividans 66 instead of S. albus 1074. 
 
6.2.2 Development and Characterization of a CRISPRa System in S. lividans 
To further develop the CRISPRa system, the rpoZ gene encoding the RNAP-ω factor was 
identified from S. lividans 66 and fused to the dCas9 protein with a double alanine linker. The 
rpoZ was fused to the C-terminal instead of N-terminal of dCas9 since a similar strategy was 
previously demonstrated in Escherichia coli and the C-terminal fusion showed better performance 
(7). Multiple sgRNAs targeting the promoter region of redD gene, activator of the red pigment 
undecylprodigiosin biosynthesis in S. lividans 66 which is silent under certain culturing conditions, 
were designed and coexpressed with the dCas9/RNAP-ω fusion protein (Figure 6.2A). Among 
eight sgRNAs, only two were observed to increase the productivity of red pigment (Figure 6.2B). 
Similar to the CRISPRa system in other organisms, the distance between the targeting region and 




6.2.3 Development and Characterization of a Titratable CRISPRi System in S. lividans 
The ability to fine tune native gene expression is critical for metabolic engineering as in many 
cases intermediate expression levels result in maximum product titer, and such a task can be 
achieved by CRISPRi system through controlling the expression level of the dCas9-sgRNA 
complex (16). In order to investigate if such a strategy is also applicable in streptomycetes, an 
inducible promoter Potr identified from Streptomyces rimousus was used to control the sgRNA 
expression (Figure 6.3A) (17). Although Potr was characterized with a broad tunable range in 
multiple streptomycetes, its background activity was sufficient to lead significant repression which 
resulted in very limited tunable range for repression (Figure 6.3B). Therefore, further improvement 
is needed to reduce the background activity and increase the tunable range. 
 
6.3 Conclusion 
In this chapter I have shown some preliminary data for developing CRISPR-based genetic 
engineering tools for streptomycetes. The activity of CRISPRi was demonstrated in both S. 
lividans 66 and S. albus J1074. By fusing the rpoZ gene encoding the RNAP-ω factor to dCas9, 
the activation of silent genes was achieved by targeting the appropriate site in the promoter region. 
In addition, titratable repression of CRISPRi by using an inducible promoter to control the 





6.4 Materials and Methods 
6.4.1 Strains and Media 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) or ThermoFisher Scientific 
(Waltham, MA). E. coli NEB® 10-beta (New England Biolabs, Ipswich, MA) was used for DNA 
manipulation. E. coli strain ET12567/pUZ800235 was a gift from Professor Eriko Takano (The 
University of Manchester, Manchester, United Kingdom) and used for plasmid conjugation. S. 
lividans 66 was obtained from the Agricultural Research Service Culture Collection (Peoria, IL). 
S. albus J1074 was a gift from Professor Wenjun Zhang (University of California, Berkeley, CA). 
ISP2, agar, beef extract, yeast extract, malt extract, and other reagents required for cell culture 
were obtained from Difco (Franklin Lakes, NJ). All restriction endonucleases and Q5 DNA 
polymerase were purchased from New England Biolabs. The QIAprep Spin Plasmid Mini-prep 
Kit, QIAquick PCR Purification Kit, QIAquick Gel Extraction Kit were purchased from Qiagen 
(Valencia, CA). Wizard Genomic DNA isolation kit was from Promega (Madison, WI). All 
primers were synthesized by Integrated DNA Technologies (Coralville, IA). MYG liquid medium 
containing 4% yeast extract, 10% malt extract, 4% glucose, MYG solid agar medium containing 
additional 2% Bacto agar and MS solid agar medium containing 2% soy bean flour, 2% maltose, 
and 2% Bacto agar were used to grow Streptomyces strains.  
 
6.4.2 Conjugation and Expression in Streptomyces species 
The CRISPR plasmids were transformed to E. coli ET12567/pUZ8002 and selected on LB agar 
plates supplemented with 25 µg/mL apramycin, 25 µg/mL kanamycin and 12.5 µg/mL 
chloramphenicol. These transformants were then used as the donors for conjugative transfer of the 
assembled plasmids to streptomycetes following the protocol described elsewhere (18). 
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Exconjugants were picked and re-streaked on MS plates supplemented with 50 µg/mL apramycin 
and grown for 3 days. For the activation of redD, a single colony was then restreaked on MYG 
plates supplemented with 50 µg/mL apramycin and incubated at 30 °C for three days. For XylE 
assay, a single colony was inoculated into 25 mL of MYG liquid medium supplemented with 50 
µg/mL apramycin in a 125 mL shake-flask (3 mm glass beads added to improve liquid mixing and 
aeration). Cells were harvested after 72 h cultivation at 30 °C, 250 rpm for XylE assay. 
Oxytetracycline was added to a final concentration of 6 µM after 6 h growth for inducible 
repression.  
 
6.4.3 XylE Assay 
Aliquots of 10 mL of the cell culture were collected and centrifuged at 4000 rpm for 10 min to 
remove the supernatant. Five milliliters of sample buffer (100 mM phosphate buffer, pH7.5; 20 
mM Na-EDTA, pH 8.0; 10% v/v acetone) was added to resuspend the cell pellets followed by 
sonication on ice for 1 min (60% amplitude, 15 s on / 30 s off). 0.1%Triton X-100 solution was 
added into the samples, which were then incubated on ice for 15 min. Then, the samples were 
centrifuged for 5 min (40,000g, 4°C), and the cell lysates were transferred to fresh tubes. 900 μL 
assay buffer (10 mM phosphate buffer, pH 7.5; 0.2 mM catechol 2,3-dioxygenase) was added to 
100μL of the cell lysate, and the change in absorbance at 375 nm (A375) was followed. The 
concentration of the total proteins was determined by the Bradford method (19). The slope of the 
linear part of the spectrophotometric output was used to calculate the specific activity of XylE as 
follows: mUcatechol dioxygenase [nmol min






Figure 6.1. CRISPRi effectively represses the expression of xylE in S. lividans 66 and S. albus 
J1074. (A) Location of the sgRNAs for CRISPRi. (B) The normalized activity of XylE in the crude 
















Figure 6.2. CRISPRa improves the productivity of undecylprodigiosin in S. lividans 66. (A) 
Location of the sgRNAs for CRISPRa. (B) S. lividans 66 transformants on ISP2 plates. The strain 






















Figure 6.3. Titratable CRISPRi controls gene expression in S. lividans 66. (A) Design of the 
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